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ABSTRACT 
Victor W. Zhong: Understanding hypoglycemia from population, individual, and behavioral 
perspectives 
(Under the direction of Elizabeth J. Mayer-Davis) 
 
Hypoglycemia (blood glucose <70 mg/dL) is a major barrier for achieving 
normoglycemia in diabetes. Three critical gaps are: i) limited data exist on describing 
longitudinal incidence of severe hypoglycemia both in patients with type 1 diabetes (T1D) and 
type 2 diabetes (T2D); ii) the relationship of HbA1c level with risk of severe hypoglycemia in 
patients with T1D or T2D remains controversial; iii) how usual dietary intake impacts on risk of 
hypoglycemia in patients with T1D is unclear.  
To address first two gaps, we used primary and secondary care data from the Clinical 
Practice Research Datalink and Hospital Episode Statistics in England. Temporal trends of 
hypoglycemia requiring hospitalization in adults with T1D (N=23,251) or T2D (N=241,829) 
from 1998 to 2013 were estimated using joinpoint regression model. By analyzing 1:6 case-
control matched dataset using conditional logistic regression models, we investigated the 
association between HbA1c level and risk of hypoglycemia hospitalization in adults with 
incident T1D (N=5,776) or T2D (N=163,237). To address the third gap, we applied logistic 
regression models to identify dietary predictors of non-severe hypoglycemia in 98 T1D 
adolescents who wore continuous glucose monitor for one week and had two days of 24-hour 
dietary recalls.  
Between 1998 and 2013 in England, the incidence of hypoglycemia hospitalizations  
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increased both in adults with T1D and T2D. In adults with T1D, compared to HbA1c 7-7.9%, 
higher HbA1c level was associated with lower risk of hypoglycemia hospitalization while lower 
HbA1c level did not increase the risk. In adults with T2D, both lower and higher HbA1c level 
increased hypoglycemia hospitalization risk (i.e., U-shape). In adolescents with T1D, lower risk 
of daytime non-severe hypoglycemia was related to higher glycemic index of the diet or higher 
intake of monounsaturated or polyunsaturated fat. Higher intake of soluble fiber or protein was 
associated with higher risk of daytime and nocturnal non-severe hypoglycemia. Adjusting for 
insulin dose per kilogram eliminated all these associations. 
Practical approaches for hypoglycemia management are urgently needed to reduce the 
fast growing hypoglycemia burden in England. Applying appropriate HbA1c treatment targets 
and appropriately matching insulin dose and injection time to freely consumed meals may reduce 
hypoglycemia risk.  
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CHAPTER 1. INTRODUCTION  
Background 
 Hypoglycemia (blood glucose ≤70 mg/dL) is common and can affect up to 60% of 
patients with type 1 diabetes and 20% of patients with type 2 diabetes within a month. Severe 
hypoglycemia requires external assistance for recovery and can be fatal. Approximately 88-98% 
of hypoglycemic events are non-severe that can result in poor quality of life. In spite of 
tremendous progress in diabetes care in the past few decades, hypoglycemia remains a major 
barrier that prevents patients with diabetes from maintaining euglycemia, in part due to the 
following three critical gaps.  
 First, data that describe longitudinal incidence of hypoglycemia in people with type 1 or 
type 2 diabetes from a population perspective are limited. During the past few decades, several 
new anti-diabetic medications for type 2 diabetes have been introduced including inhibitors of 
dipeptidyl peptidase-4 (DPP-4), inhibitors of sodium-glucose co-transporter-2 (SGLT-2), and 
glucagon-like peptide-1 (GLP-1) agonists. They are associated with low hypoglycemia risk. 
Also, new insulin products and new technologies (e.g., insulin pump, continuous glucose 
monitor (CGM)) may assist in improving glycemic control, particularly for type 1 diabetes. 
Importantly, diabetes treatment guidelines have recently evolved from emphasizing 
hyperglycemia management towards recommending individualized glycemic targets to balance 
long-term glycemic benefits and short-term hypoglycemia risk. It is not known if these changes 
have led to a reduction in hypoglycemia risk in diabetes, and if the trends of hypoglycemia differ 
by diabetes type. Second, according to current diabetes guidelines, deciding a person’s HbA1c 
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treatment target may need to consider this individual’s hypoglycemia risk factors including age, 
diabetes duration, comorbidities, current use of anti-diabetic drug(s), life expectancy, and history 
of hypoglycemia. However, the association between HbA1c level and risk of hypoglycemia 
remains unclear. It is not known if the association differs by diabetes type or patient 
hypoglycemia risk factors. Finally, dietary intake is a major determinant of blood glucose 
concentrations. Current nutrition guidelines have specific recommendations for treating 
hypoglycemia; glucose, sucrose or any form of carbohydrates are to be immediately 
administered. However, information regarding whether or how usual dietary intake influences 
risk of hypoglycemia is limited.  
 Available data allowed us to study the first two gaps in adults and the third gap in 
adolescents. To address the first two gaps, we used primary care data from the Clinical Practice 
Research Datalink (CPRD) in the United Kingdom (UK) and secondary care data from the 
Hospital Episode Statistics (HES) in England. The CPRD currently includes over 15 million 
patient records, drawn from more than 680 practices nationwide. The HES is a data warehouse 
storing records of all patients admitted to National Health Service hospitals in England. The 
CPRD and HES can be linked via an independent third-party. The large population from the 
CPRD and HES allowed us to evaluate longitudinal trends of severe hypoglycemia for both type 
1 and type 2 diabetes from a population perspective. It also offered an opportunity to determine 
the relationship between HbA1c level and risk of severe hypoglycemia by diabetes type and 
evaluate important effect modifications. To address the third gap, we used baseline data from a 
subset of 258 adolescents with type 1 diabetes from the Flexible Lifestyles (FL3X) randomized 
trial (ClinicalTrials.gov identifier: NCT01286350), which is a 18-month efficacy study with the 
primary goal of improving glycemic outcomes and quality of life in adolescents with type 1 
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diabetes. Participants wore CGM for one week during which two 24-hour dietary and physical 
activity recalls were collected.  
 
Research Aims 
Aim 1. To describe incidence and trends in hypoglycemia hospitalizations in adults with 
type 1 or type 2 diabetes from 1998 to 2013 in England.  
 In Aim 1, the goal is to characterize incidence and longitudinal trends of hypoglycemia 
requiring hospitalization among adults with type 1 or type 2 diabetes between 1998 and 2013, 
both overall and according to key patient characteristics including age, gender, diabetes duration, 
and current anti-diabetic medication (for type 2 diabetes only). 
 We hypothesize that annual incidence rates increase first and then decrease due to the 
recent negative findings on the cardiovascular benefits of more aggressive glycemic control 
therapy in 2008-2009. The slope may vary by diabetes type, demographics, duration of diabetes 
or current anti-diabetic medication.  
 
Aim 2. To determine the relationship between HbA1c level and risk of hypoglycemia 
hospitalization in adults with type 1 or type 2 diabetes.  
 In this aim, the primary goal is to determine the association between recently measured 
HbA1c level and risk of hypoglycemia hospitalization. HbA1c is a widely used marker of 
chronic glycemia, reflecting average blood glucose levels over a 2- to 3-month period of time. 
We define HbA1c measured within 3 months of hypoglycemia hospitalization as recent HbA1c, 
which is more relevant to hypoglycemia as an acute complication of diabetes than earlier HbA1c 
measurements. Also, we aim to determine whether the association between recently measured 
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HbA1c level and risk of hypoglycemia hospitalization is modified by age, gender, diabetes 
duration, weight status, comorbidities, and current anti-diabetic medication.  
 
Aim 3. To determine the association between usual dietary intake and risk of non-severe 
hypoglycemia in adolescents with type 1 diabetes. 
 We use averaged intake from two 24-hour dietary recalls to represent usual dietary intake 
in the CGM-wearing week at baseline. Due to different etiology between daytime and nocturnal 
hypoglycemia and different dietary behaviors between daytime and nighttime, we study daytime 
hypoglycemia and nocturnal hypoglycemia separately.  
 We hypothesize that higher intake of fat or protein reduces risk of both daytime and 
nocturnal non-severe hypoglycemia. A diet low in glycemic index (GI) or high in fiber increases 
the risk of both daytime and nocturnal non-severe hypoglycemia.  
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CHAPTER 2: LITERATURE REVIEW 
A. Overview on diabetes and hypoglycemia 
Section 1. Diabetes 
Considerable and fast-increasing diabetes burden 
 The International Diabetes Federation reported a diabetes prevalence of 8.3% in adults 
worldwide in 2013, representing 382 million people.1 In less than 25 years, the number of people 
with diabetes will rise to more than 592 million. Just within 5 years in the United States (US), the 
estimated total economic cost of diagnosed diabetes increased from $174 billion in 20072 to $245 
billion in 2012.3 By 2050, one in three US adults is predicted to have diabetes.4 In the UK, there 
were 2.6 million people with diagnosed diabetes in 2009 and this number may be increased to 
more than 4 million by 2025.5 The burden of diabetes has also been increasing at a fearsome 
pace in many developing countries. A national study in 2010 revealed that the prevalence of 
diabetes was 11.6% in Chinese adults.6 In India, the number of diabetes doubled between 1995 
and 2005.7 There were about 61.3 million patients with type 2 diabetes in 2011 and the predicted 
number is about 101.2 million by 2030 in India.1, 7 Undoubtedly, the diabetes pandemic poses 
enormous public health and economic challenges globally, currently and into the future. 
 
Importance of distinction between type 1 and type 2 diabetes 
 Type 1 and type 2 diabetes are two major types of diabetes.8 Both can occur in people of 
any age. They are two very different diseases, although increased blood glucose is a major 
common symptom. Type 1 diabetes, previously known as insulin-dependent diabetes or juvenile-
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onset diabetes, accounts for about 5-10% of those with diabetes. Type 1 diabetes is generally 
caused by a cellular-mediated autoimmune destruction of the beta-cells in pancreas.8 Type 1 
diabetes is commonly diagnosed in children or young adults with about 75% of the cases 
diagnosed in individuals <18 years of age.9 Patients need insulin every day to control blood 
glucose. The prevalence of type 1 diabetes has been increasing, but the reasons are not clear;1 
possible reasons are changes in environmental risk factors, diet in early life, and viral infections.  
 About 90-95% of all diabetes are type 2 diabetes, previously known as non-insulin-
dependent diabetes or adult-onset diabetes.8 Individuals with type 2 diabetes have insulin 
resistance and usually relative (rather than absolute compared to type 1 diabetes) insulin 
deficiency. Many patients can manage diabetes through lifestyle change alone in early stages. 
Monotherapy or a combination of oral anti-diabetic drugs may suffice as the disease progresses. 
As capacity of the pancreas to secrete adequate insulin declines over time, patients commonly 
need insulin, specifically among the elderly or advanced type 2 patients.10 Most of type 2 
patients are diagnosed during middle adulthood or older.8 However, recently and although still 
rare, the prevalence of type 2 diabetes has been increasing in children and adolescents, 
particularly among non-white racial and ethnic populations, likely related to the increasing 
prevalence of obesity.11  
 Because of the different etiology and treatment strategies explained above between type 1 
and type 2 diabetes, risk of hypoglycemia is generally higher in type 1 than type 2 diabetes.12 
However, hypoglycemia risk is also high in the elderly patients with type 2 diabetes or type 2 
patients treated with insulin, sulfonylureas or glinide.12, 13 
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Diabetes in children and adults 
 The previous section described that in children, type 1 diabetes is the predominant type of 
diabetes while type 2 diabetes is the predominant type in adults. Further, the diabetes treatment 
strategies may be different between children and adults, and between type 1 and type 2 
diabetes.9, 14 Diabetes in children has a number of unique features including insulin 
sensitivity/resistance influenced by physical growth and sexual maturation, capability of self-
care, supervision in the child care and school environment, neurological vulnerability to hypo- 
and hyperglycemia, and neurocognitive impact of diabetic ketoacidosis.9 A general glycemic 
goal with HbA1c <7.5% is recommended for children of all ages.9 In adults, a general glycemic 
target of <7.0% is recommended, although more or less stringent goal may be applied to specific 
individuals.15  Therefore, diabetes research should be clear about study population (pediatric 
versus adult, or both) and the type of diabetes of interest. In terms of the risk of hypoglycemia, 
children are more vulnerable, because of the challenges presented by inaccurate insulin dosing, 
variable eating patterns, erratic activity and the child’s capacity to detect hypoglycemia.12   
 
Section 2. Hypoglycemia  
Definition of hypoglycemia, severe and non-severe hypoglycemia  
 A blood glucose of <70 mg/dL is recommended by the American Diabetes Association 
(ADA) and The Endocrine Society to define hypoglycemia.12 Hypoglycemia occurs more often 
in individuals with type 1 diabetes compared to type 2 diabetes. In type 2 diabetes, most episodes 
of hypoglycemia happen to elderly patients or patients treated with insulin, sulfonylureas or 
glinide.12, 13 Hypoglycemia can be severe or non-severe (i.e., mild or moderate). Severe 
hypoglycemia is defined as a low blood glucose event requiring assistance of another person to 
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actively administer carbohydrates, glucagon, or take other corrective actions.12  Hypoglycemia 
leading to emergency department visit or hospital admission is also considered as severe 
hypoglycemia.16, 17 Hypoglycemia that is not severe enough of requiring external help or 
emergency department visit or hospital admission is termed non-severe hypoglycemia. 
 
Impacts and consequences of hypoglycemia  
 Despite the great advance in the knowledge of diabetes management and related 
technology, optimal glycemic control has not been satisfactorily achieved in many patients with 
diabetes. A primary limiting factor is hypoglycemia.18 Severe hypoglycemia has been 
independently associated with an increased risk of cardiovascular disease,19 dementia,20 cancer,21 
and death.22, 23 Furthermore, a recent meta-analysis of 13 randomized trials suggests that the 
harms associated with severe hypoglycemic events could even negate the benefits of intensive 
glucose reduction.24  
 Mild and moderate hypoglycemia, accounting for 88-98% of the total hypoglycemia 
episodes,25 can as well decrease quality of life of patients with diabetes and may increase 
mortality.26 Management of non-severe hypoglycemia accounts for up to 13% of all out-of-
pocket costs related to diabetes.27 A survey of people with diabetes in the US, UK, Germany, and 
France found that, over a 1-month period, mean losses in workplace productivity were estimated 
to range from $15.26–93.47 per non-severe hypoglycemia episode, representing 8.3 to 15.9 
hours of lost work time per month.28 
 Further, fear of hypoglycemia causes exaggerated avoidance behavior and consequently 
suboptimum insulin therapy and poor glycemic control.25  Fear of hypoglycemia may cause 
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patients to decline participation in physical activity, thus limiting these patients’ receipt of the 
many benefits of physical activity.29, 30 
 Hypoglycemia in children needs particular attention. Children are most vulnerable to the 
adverse consequences of hypoglycemia, because their brains are still developing.12 They are at 
high risk of brain dysfunction and neurological sequelae of hypoglycemia. Repeated episodes of 
severe hypoglycemia may even cause permanent damage to the brain with structural changes in 
the white and gray matter of developing brains.31 
 
Section 3. Advances in diabetes management in the previous two decades 
 Two decades ago, the Diabetes Control and Complications Trial (DCCT),32  
demonstrated the convincing microvascular benefits of tight glycemic control. In years following 
the DCCT study, controlling HbA1c under 6.5-7.0% for individuals with diabetes was the 
common clinical practice,33, 34 and a near-normal HbA1c <6% can also be considered based on 
individual assessment.35 With a few exceptions,13, 33 most diabetes guidelines did not place much 
emphasis, until very recently, on adjusting glycemic targets through evaluating individual’s 
hypoglycemia risk factors including prior history of severe hypoglycemia, advanced age, limited 
life expectancy, and comorbidities.14, 15, 36 Although more stringent glycemic control improves 
HbA1c and reduces various macrovascular and microvascular complications, it increases risk of 
severe hypoglycemia.37-39 A meta-analysis of 13 randomized trials suggests that the harm 
associated with severe hypoglycemia could even negate the benefit of intensive glucose 
reduction.24  Further, three large clinical trials published in 2008-2009 provide persuasive 
evidence that applying intensive therapy to all patients with diabetes may not gain macrovascular 
benefits.40-42 Instead, it may be associated with a broad range of potential harms and death 
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followed by increased risk of severe hypoglycemia.43, 44 Accordingly, most current guidelines 
suggest that individualized glycemic targets may be more appropriate to balance hyper- and 
hypoglycemia risk.14, 15  
 Further, in the past few decades, several new anti-diabetic drugs have been introduced 
including DPP-4 inhibitors, SGLT-2 inhibitors, and GLP-1 agonists. All of these drugs do not 
usually cause hypoglycemia unless combined with therapies that can cause hypoglycemia.45, 46 
Also, new insulin products, improved insulin delivery methods and dosing algorithm, and 
continuous glucose monitoring are likely to help patients with diabetes to better control blood 
glucose within a reasonable range.47-49 Additionally, standards for diabetes self-management and 
education have been established.50 All these critical changes in the previous few decades may 
contribute to improvement of diabetes control including reduction of hypoglycemia risk in 
patients with type 1 and type 2 diabetes.  
 
B. Previous studies related to describing trends of severe hypoglycemia   
Evidence in the US  
 Three studies reported temporal trends of severe hypoglycemia in people with diabetes 
without differentiating between type 1 and type 2 diabetes (Table 2).51-53 Only one study 
investigated trends of severe hypoglycemia specifically in adults with type 2 diabetes.54 Trends 
in type 1 diabetes have not been studied. Lipska et al.51 reported trends of hospital admissions for 
hypoglycemia among Medicare beneficiaries between 1999 and 2011. Limitations of this 
investigation included not accounting for diabetes prevalence, difficulty in defining the 
denominator, and no differentiation between type 1 and type 2 diabetes. Further, these results  
could not be generalized to the US population ≤64 years of age. Ginde et al.52 used the National
  
 
 
1
1
 
Table 2. Selected studies reporting on trends of hypoglycemia 
First author Location  Period Data source Population Outcome Main findings 
Lipska KJ,54 
Diabetes Care. 
2016 
US 
2006-
2013 
OptumLabs Data 
Warehouse  
 
Adults with 
type 2 
diabetes 
Hypoglycemia 
requiring emergency 
room visit or hospital 
admission or 
observation stay 
 
The overall rate of severe 
hypoglycemia remains largely 
unchanged. 
Wang J,53  
PLoS One. 
2015 
US 
2006-
2011 
Nationwide 
Emergency 
Department 
Sample 
Adults with 
diabetes 
Emergency department 
visit for hypoglycemia 
Hypoglycemia rates have 
declined for all adults but 
persons aged 18-44 years. 
Lipska KJ,51 
JAMA Intern 
Med. 2014 
US 
1999-
2011 
Inpatient National 
Claims History 
files from the 
Centers for 
Medicare and 
Medicaid Services 
Elderly adults 
Hypoglycemia 
requiring hospital 
admission 
Admissions for hypoglycemia 
increased until 2007, and 
declined subsequently, but 
remained above the baseline 
(1999) levels. 
Ginde AA,52 
Diabetes Care. 
2008 
US 
1993-
2005 
National Hospital 
Ambulatory 
Medical Care 
Survey 
All people 
with diabetes 
Emergency department 
visits for hypoglycemia 
While the total number of visits 
for hypoglycemia increased 
during the study period, the rate 
per diabetic population or 
emergency department visits 
did not change significantly. 
 
Zaccardi F,55 
Lancet Diabetes 
Endocrinol. 
2016 
 
England 
2005-
2014 
Hospital Episode 
Statistics 
All people  
Hypoglycemia 
requiring hospital 
admission 
Over 10 years, hospital 
admissions in England for 
hypoglycemia increased by 
39% in absolute terms and by 
14% considering the general 
increase in hospitalization; 
however, accounting for 
  
 
 
1
2
 
diabetes prevalence, there was 
a reduction of admission rates. 
 
Clemens KK,56 
PLoS One. 
2015 
Ontario, 
Canada 
2002-
2013 
Linked health care 
databases 
Elderly adults 
with diabetes  
Emergency room visit 
or inpatient admission 
for hypoglycemia  
Although the absolute number 
of treated patients with a 
hypoglycemia encounter 
increased until mid-2006 and 
then decreased, the overall 
percentage with an encounter 
declined over the study period. 
Booth GL,57 
Diabetes Care. 
2005 
Ontario, 
Canada 
1994-
1999 
Ontario Diabetes 
Database and 
hospital discharge 
abstracts prepared 
by the Canadian 
Institute for Health 
Information 
Adults with 
diabetes 
Hypoglycemia 
requiring hospital 
admission 
Rates of hospitalization for 
hypoglycemic emergencies 
decreased by 76.9%. 
Chen YJ,58 
Prim Care 
Diabetes. 2015 
 
Taiwan 
2000-
2010 
National Health 
Insurance 
Research Database 
Middle-aged 
or elderly 
adults with 
type 2 
diabetes 
Emergency department 
visit for hypoglycemia 
Within a 10-year period, there 
was a substantial increase in the 
rates of hypoglycemia-related 
emergency department visits 
from type 2 diabetic patients in 
Taiwan. 
Lombardo F,59 
PLoS One. 
2013 
 
Italy 
2001-
2010 
National Hospital 
Discharge 
Database 
All people 
with diabetes 
Hypoglycemic coma 
Decreased rate of 
hypoglycemic coma. 
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Hospital Ambulatory Medical Care Survey to characterize national trends in hypoglycemia 
admitted to emergency department between 1993 and 2005. Although Ginde et al. analyzed a 
representative sample of all US non-institutional general and short-stay hospitals, diabetes type-
specific trends were not available. Additionally, data presented pertained to emergency 
department visits, not individual patients. According to Wang et al.,53 rates of emergency 
department visits for hypoglycemia declined for all adults but persons aged 18-44 years from 
2006 to 2011. Again they did not distinguish between type 1 and type 2 diabetes and reported 
visit-level estimates only. Using claims data, Lipska et al.54 found that the overall rate of 
hypoglycemia requiring emergency department visit or hospital admission or observation stay 
remained largely unchanged between 2006 and 2013 in adults with type 2 diabetes. However, 
these were privately insured patients and may not be representative of all patients with type 2 
diabetes. 
 
Evidence in other countries  
 Recently, using the HES database, Zaccardi et al.55 reported a 10-year trends (2005-2014) 
in hospital admissions for hypoglycemia in England. The hospital admission rate for 
hypoglycemia increased by 14% in England, but the hospital admission rate showed a reduction 
after accounting for prevalence of diabetes. Still, Zaccardi et al. did not investigate the trends by 
diabetes type. A study in Taiwan assessed hypoglycemia trend specifically in adults with type 2 
diabetes; Chen et al.58 reported an increasing trend in the incidence of hypoglycemia-related 
emergency department visits from 2000 to 2010. However Chen et al. excluded patients younger 
than 45 years old. A nationwide study in Italy reported temporal trend in hospitalization for 
hypoglycemic coma between 2001 and 2010, but other specified and unspecified severe 
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hypoglycemia was not evaluated.59 Two studies from Ontario, Canada reported decreased rates 
of hypoglycemia leading to emergency room or hospitalization.56, 57 All these last three studies 
were not able to describe diabetes type-specific trend. 
 In summary, the primary limitation of the current literature is without being able to 
provide estimates of diabetes type-specific hypoglycemia trend from a population perspective, 
both overall and by subgroups such as use of anti-diabetic medication. Thus, clear clinical 
messages could not be given such as who are at increased/decreased risk of hypoglycemia over 
time, which subgroups have the greatest increase/decrease in hypoglycemia risk, and which 
subgroups have the highest/lowest hypoglycemia burden.  
 
C. HbA1c level and severe hypoglycemia  
 The goal of diabetes treatment is to control blood glucose and prevent complications and 
HbA1c is the main treatment target. Improved HbA1c over time prevents or delays 
microvascular complications—retinopathy, nephropathy, and neuropathy—in patients with type 
1 diabetes32 or type 2 diabetes;60, 61 and may reduce macrovascular events.32, 60, 61 As explained 
above, current diabetes guidelines recommend personalized glycemic targets to balance long-
term glycemic benefits and short-term hypoglycemia risk.14, 15, 62, 63 More specifically, deciding 
an individual’s HbA1c treatment goal needs to consider this person’s hypoglycemia risk factors 
including age, diabetes duration, comorbidities, current use of anti-diabetic drug(s), life 
expectancy, and history of hypoglycemia. However, the association between HbA1c level and 
risk of severe hypoglycemia remains unclear.  
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HbA1c level and severe hypoglycemia in patients with type 1 diabetes 
 Evidence from the DCCT and other studies in the previous decades have revealed an 
inverse association between HbA1c and risk of severe hypoglycemia in adults32 and children 
with T1D 64-66. However, recent studies reported no association between HbA1c and the 
incidence of severe hypoglycemia 67-70. A trend analysis on a large cohort of patients with type 1 
diabetes from the Diabetes Patienten Verlaufsdokumentation (DPV) Initiative found that the 
previous strong association of HbA1c level between 6.0% - 7.9% with severe hypoglycemia has 
considerably decreased from 1995 to 2012.71 Therefore, the HbA1c-hypogliycemia relationship 
remains unclear in type 1 diabetes. 
 
HbA1c level and severe hypoglycemia in patients with type 2 diabetes 
 In patients with type 2 diabetes, a number of large randomized clinical trials provides 
persuasive evidence that near normal or good glycemic control increased risk of severe 
hypoglycemia.40-42 However, post hoc analyses of the Action to Control Cardiovascular Risk in 
Diabetes study reported that the risk of severe hypoglycemia was increased among participants 
with poorer glycemic control compared to those with more desirable HbA1c, irrespective of 
assigned treatment group.72 A cross-sectional survey on patients from an integrated health care 
system in the US found a U-shape relationship between HbA1c and risk of severe hypoglycemia 
73. However, this relationship has not been confirmed in other large cohorts of patients with T2D 
from the usual care setting.  
 In both type 1 and type 2 diabetes, the majority of investigations mentioned above did not 
evaluate possible critical interactions between HbA1c and important patient characteristics that 
are related to hypoglycemia vulnerability including age, diabetes duration, comorbidities, and 
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specific glucose-lowering medications. Further, HbA1c measured within 2-3 months of 
hypoglycemic events may be more relevant to the acute event of severe hypoglycemia. However, 
previous studies used “baseline” HbA1c values measured more than three months or even years 
before,38, 72-75 which may be less predictive of severe hypoglycemia and more likely to be 
confounded given the big time gap in between.  
 
D. Dietary intake and hypoglycemia in children  
Lacking nutrition recommendations for hypoglycemia prevention  
 Hypoglycemia is the consequence of a mismatch between insulin dose, food consumed, 
and recent exercise.31 Hypoglycemia is manageable though behavioral intervention.30 As a major 
determinant of blood glucose, nutrition therapy plays a key role in managing hypoglycemia in 
diabetes.76 Current recommendations from the ADA77 and International Society for Pediatric and 
Adolescent Diabetes (ISPAD)30 suggest using glucose, sucrose or any form of carbohydrate to 
treat hypoglycemia. However, specific dietary recommendations for preventing hypoglycemia 
are limited, particularly for children. Evidence from adults with type 2 diabetes may not be 
applicable to children with type 1 diabetes. For example, a position statement from the ADA 
presents nutrition therapy recommendations for adults with type 2 diabetes, in which protein is 
not recommended to either treat or prevent hypoglycemia.76 The reason is that ingested protein 
appears to increase insulin secretion in type 2 diabetes without increasing blood glucose 
concentrations and thus may increase hypoglycemia risk.78, 79 However, the glycemic effect of 
protein is likely to be different between type 1 and type 2 diabetes, because pancreas of patients 
with type 1 diabetes has minimal insulin secretion capability, although residual insulin secretion 
in youth with type 1 diabetes may be relevant.80, 81 In fact, a clinical trial conducted by Smart et 
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al.82 found that high protein diet substantially reduced the risk of hypoglycemia in children with 
type 1 diabetes when consumed with carbohydrate.  
 
Carbohydrate, protein, fat, and hypoglycemia  
 The majority of the literature in children with type 1 diabetes focuses on postprandial 
glycemic excursions following experimental meals with different macronutrients composition in 
clinical trial settings. Hypoglycemia is rarely studied as a primary outcome. Available data, 
though very limited in children, suggest that quality of carbohydrate matters for prevention of 
hypoglycemia. Published studies consistently reported that higher fiber intake was associated 
with lower postprandial blood glucose.83, 84 Lafrance et al.83 found that high-fiber diet did not 
increase the risk of hypoglycemia, although lower mean blood glucose was seen with high-fiber 
diet compared to low-fiber diet, in well-controlled patients with type 1 diabetes on intensive 
insulin therapy. Convincing evidence has shown that low GI foods and meals produce lower 
glycemic responses in people with diabetes.83, 85-87 However, the relationship between the GI and 
risk of hypoglycemia is inconsistent. Opposite results were reported, possibly due to the very 
different definition of high- and low-GI diet in these studies and different length of blood 
glucose monitoring.83, 86, 87 
 Expanding evidence suggests that carbohydrate does not fully explain postprandial 
glycemic excursions.82, 88, 89 Fat and protein, when consumed with carbohydrate, can cause 
sustained late high postprandial blood glucose up to or over 5 hours.90 And protein and fat may 
have an additive impact on blood glucose independent of carbohydrate.82 However, none of 
previous studies differentiated fat type. Therefore, it is not known if saturated fat and unsaturated 
fat have similar glycemic effect. The effect of protein on blood glucose excursions is 
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complicated. Protein may have very different effects when consumed with and without 
carbohydrate. Paterson et al.91 examined the effect of protein only (without intake of 
carbohydrate and fat) and found that consuming 12.5–50 grams of protein did not influence 
blood glucose, although consuming 75-100 grams of protein significantly increased glucose 
concentrations, causing an increase in glucose concentrations similar to that of consuming 20 
grams of carbohydrate without injecting insulin. 
 
Differential effects of dietary intake on daytime and nocturnal hypoglycemia  
 The effects of dietary intake on daytime and nocturnal hypoglycemia may be different. 
Current insulin preparations do not adequately mimic normal physiologic patterns of insulin 
secretion92 and sleep attenuates counter-regulatory responses to hypoglycemia.93 Further, dietary 
intake and exercise94 as two major determinants of blood glucose occur mainly in the daytime. A 
clinical trial conducted in children with type 1 diabetes found no differences in the mean blood 
glucose and hypoglycemia risk in the night between consuming a low-GI and a high-GI diet, 
although the mean blood glucose was lower and hypoglycemia risk was higher in the daytime.86 
However, these findings have not been confirmed in an outpatient setting. Further, it is not 
known if differential effects on the risk of daytime and nocturnal hypoglycemia exist for major 
macronutrients.  
 In summary, the majority of above studies are clinical trials. Few investigations have 
studied the effect of usual dietary intake on the risk of hypoglycemia in free-living youth with 
diabetes, which associates typical dietary patterns with day-to-day glycemic control.84 Further, 
most studies have not studied hypoglycemia as the primary outcome. We do not know if dietary 
intake predictive of postprandial blood glucose is also associated with occurrence of 
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hypoglycemia. In addition, it may be important to differentiate between daytime and nocturnal 
hypoglycemia for studying dietary effects on blood glucose excursions. To address these gaps, 
our project will investigate the effect of usual dietary intake on the risk of daytime and nocturnal 
hypoglycemia in free-living adolescents with type 1 diabetes.  
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CHAPTER 3. INCIDENCE AND TEMPORAL TRENDS IN HYPOGLYCEMIA 
HOSPITALIZATIONS IN ADULTS WITH TYPE 1 AND TYPE 2 DIABETES IN 
ENGLAND, 1998 TO 2013: A RETROSPECTIVE COHORT STUDY 
 
Introduction  
 Severe hypoglycemia frequently occurs in people with type 1 diabetes and can also occur 
in individuals with type 2 diabetes, particularly among elderly people or those treated with 
insulin or sulfonylureas.12 In the two decades following the DCCT,32 diabetes treatment 
guidelines have evolved from emphasizing hyperglycemia management with achieving HbA1c 
<6.5-7.0% towards recommending individualized glycemic targets to balance long-term 
glycemic benefits and hypoglycemia risk.14, 15 For example, less stringent HbA1c goals (e.g., 
<8.0%) may be appropriate for patients with a history of severe hypoglycemia, limited life 
expectancy, extensive comorbid conditions, or long duration of diabetes. Conversely, more 
stringent HbA1c goals (e.g. <6.5%) may be applied to individuals with short duration of 
diabetes, few comorbidities, long life expectancy, or treated with lifestyle or metformin only.14, 15 
Particularly, the argument for individualization of glycemic targets was further supported by 
evidence from three recent clinical trials – the Action to Control Cardiovascular Risk in Diabetes 
(ACCORD) trial,40 the Action in Diabetes and Vascular Disease (ADVANCE) trial,41 and the 
Veterans’ Administration Diabetes Trial42 (VADT) – that consistently reported no macrovascular 
benefits of intensive therapy, but revealed a broad range of potential harms and death followed 
by increased risk of severe hypoglycemia.43, 44
 21 
 
 It is not clear whether changes in clinical practice guidelines that resulted from this 
evidence base have led to a change in severe hypoglycemia risk in adults with diabetes. The 
majority of published studies quantified frequencies of severe hypoglycemia using cross-
sectional13, 16, 95 or clinical trial data96 and thus are not appropriate for assessing temporal trends 
from a population perspective. A few studies on trends in hypoglycemia incidence are available, 
but they are limited to middle-age and/or elderly adults,51, 58 visit-level estimates,52 or a short-
term early trend in 1994-1998.57 Further, the epidemiology of severe hypoglycemia differs 
considerably by diabetes type,12 yet most studies do not distinguish between type 1 and type 2 
diabetes.51, 52, 59, 97  
 In the present study, we aimed to study hypoglycemia that requires hospital admission, 
which is a most severe form of hypoglycemia and associated with considerable morbidity, 
mortality, healthcare resources use, and expenditure.98  The main goal was to characterize 
incidence and longitudinal trends of hypoglycemia hospitalizations among adults with type 1 and 
type 2 diabetes between 1998 and 2013, both overall and according to key patient characteristics. 
Data for analyses were from the CPRD and HES from the UK.  
 
Methods 
Two data sources: the CPRD and HES 
 Established in 1987, the CPRD included 684 practices from England, Scotland, Wales 
and Northern Ireland and contained over 15 million patient records as of January 2015. Patients 
in the CPRD are representative of age, gender and geographic regions of the UK.99 The CPRD 
contains detailed longitudinal primary care information including, but not limited to, 
demographics, clinical diagnoses, prescriptions, laboratory test results and hospital referrals. 
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Clinical entries in the CPRD are coded using Read codes, which is a hierarchical clinical coding 
system used in General Practice in the UK.100 
 The HES is a data warehouse storing records of all patients admitted to National Health 
Service hospitals in England (not Northern Ireland, Scotland or Wales). Patient-level data from 
consenting CPRD practices are linked to the HES data via a trusted third party.99 The HES data 
utilized for the current study included admitted patient care information from April 1, 1997 to 
March 31, 2014. ICD-10 codes  (international classification of diseases, 10th revision) are used 
within the HES, which were mandated for use in the UK starting in 1995. 
 Hypoglycemia hospitalizations were identified from the HES. All other information 
including diabetes diagnosis, demographics and anti-diabetic drug prescriptions were extracted 
from the CPRD.  
 
Definition of type 1 and type 2 diabetes 
 As of March 31, 2014, 384 of the 684 CPRD practices were linked to the HES data and 
thus were included in our study, accounting for approximately 60% of the entire CPRD 
population. Patients with ≥1 diabetes related Read code were first identified.101 Patients were 
next excluded if they had any record of secondary diabetes, maturity onset diabetes of young, 
latent autoimmune diabetes in adults, malnutrition related diabetes, or considered not to be of 
research standard by the CPRD team.  
 Criteria to identify diabetes cases and type were adopted from relevant CPRD literature 
with modifications to reflect specific differentiation between type 1 and type 2 diabetes.102-104 
Among those with at least one diabetes related code, type 1 diabetes was identified if one of the 
following three criteria was met: (i) ≥1 type 1 code and use of insulin only; (ii) ≥1 type 1 code 
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and use of insulin only on the diagnosis date and oral anti-diabetic drug (OAD), if any, was 
introduced 6 months later; (iii) ≥2 insulin prescriptions only and ≥1 unspecified diabetes code. 
Type 2 diabetes was defined as any of the following: (i) ≥2 type 2 codes and 0 type 1 code, 
regardless of drug use; (ii) ≥1 type 2 code and 0 type 1 code and OAD only; (iii) ≥1 type 2 code 
and 0 type 1 code and on OAD and insulin, but oral drug prescribed no later than insulin; (iv) ≥2 
classes of OAD; (v) ≥2 prescriptions of a non-insulin non-metformin diabetes related drug only. 
OAD included metformin, sulfonylureas, glinide, thiazolidinediones, DPP-4 inhibitors, SGLT-2 
inhibitors, GLP-1 agonists, and acarbose. 
 
Study period and definition of hypoglycemia hospitalization 
 The study period was between January 1, 1998 and December 31, 2013 when full-year 
HES data were available. The follow-up started at the maximum date of January 1 1998, first 
date of diabetes visit, patient registration, Up To Standard (UTS) date or 18 years old. UTS is the 
date at which the practice data is deemed to be of research quality.99 Follow-up ended at the 
minimum date of December 31 2013, death, transfer out or last data collection for the practice. 
Hypoglycemia (E16.0, E16.1 and E16.2) listed as primary diagnosis for hospitalization during 
the follow-up period was identified.  
 
Statistical analysis 
 All analyses were performed separately for adults with type 1 diabetes and type 2 
diabetes. Treatment guidelines for type 2 diabetes vary according to individual’s hypoglycemia 
risk factors, such as age, current anti-diabetic medications, number of comorbidities, duration of 
diabetes, history of severe hypoglycemia, and life expectancy.14, 15 Therefore, separate analyses 
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were performed in young and middle-aged adults (18-64 years) with type 2 diabetes and elderly 
adults (≥65 years) with type 2 diabetes. 
 Incidence rate    Incidence rates of hypoglycemia hospitalizations were calculated by 
dividing the total number of hypoglycemia hospitalizations by total accumulated person-years 
with diabetes within each year between 1998 and 2013. All episodes of hypoglycemia 
hospitalizations from a patient during the follow-up period specified above were included. The 
accumulated person-years for a patient was obtained by subtracting the follow-up start date from 
the follow-up end date, which was then divided by 365.25.  
 Stratified incidence rates were also computed. For adults with type 1 diabetes, incidence 
rates were calculated by age (18-44, 45-64, 65-79, ≥80 years), gender (male or female), diabetes 
duration (0-4, 5-9, 10-14, ≥15 years). For young and middle-aged adults with type 2 diabetes, 
incidence rates were calculated by age (18-44, 45-64 years), gender, diabetes duration (0-9, ≥10 
years) and current use of anti-diabetic drugs (insulin with/without OAD, sulfonylureas 
with/without other OAD, and “other”). For elderly adults with type 2 diabetes, incidence rates 
were calculated by age (65-79, ≥80 years), gender, diabetes duration (0-4, 5-9, 10-14, ≥15 years), 
and current use of anti-diabetic drugs (insulin only, insulin and OAD, sulfonylureas only, 
sulfonylureas and other OAD, and “other”). All rates were reported per 1000 person-years. 
 Trend analysis   We applied joinpoint regression models to quantify temporal trends for 
both overall and stratified incidence rates.105 Each joinpoint (i.e., specific year) denoted a 
statistically significant change in trend. We fitted a heteroscedastic and uncorrelated error 
joinpoint regression model, and allowed a maximum of 3 joinpoints. A grid search was 
employed to identify locations of joinpoint(s). We selected the best fitting model by conducting a 
series of permutation tests based on 4,500 Monte Carlo replicates, using a Bonferroni correction 
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for multiple testing.106 Parameters in the model were estimated using weighted least squares with 
weights proportional to the inverse of the variance of the incidence rate at each year. Annual 
percentage change and 95% CI were estimated.  
 Negative binomial model    We fitted a negative binomial regression model with the 
number of hospitalizations as the outcome and the logarithm of person-years as the offset to 
determine risk factors and change in the incidence rate of hypoglycemia hospitalizations by year. 
Using year 1998 as the reference year, we included 15 dummy year variables, representing 
subsequent years from 1999 to 2013, age (18-44, 45-64, 65-79, ≥80 years), gender, duration of 
diabetes (0-4, 5-9, 10-14, ≥15 years) and current use of anti-diabetic drugs (for type 2 diabetes 
only: self-management alone without using insulin or any OAD, metformin only, sulfonylureas 
only, sulfonylureas and other OAD, insulin only, insulin and OAD, and “other”). Incidence rate 
ratio (IRR) and 95% CI were estimated.  
 Additional analyses    Using identical methodologies described above, the incidence rates 
and trends in first hypoglycemia hospitalization were also studied, among adults with incident 
type 1 and type 2 diabetes between 1998 and 2013. Patients with incident type 1 and type 2 
diabetes between January 1, 1998 and December 31, 2013 were identified as those with the first 
diabetes visit date >365 days after registration.102    
 SAS (version 9.4, SAS Institute Inc.) and Joinpoint software were used to perform 
analyses.105 Statistical significance was indicated by a two sided P value <0.05. 
 
Patient involvement 
 No patients were involved in setting the research question or the outcome measures, nor 
were they involved in developing plans for design or implementation of the study. There are no 
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plans to involve patients in the dissemination of results, nor will we disseminate results directly 
to patients. 
 
Results 
 Among 23,251 adults with type 1 diabetes (Figure 3.1), 1,591 hypoglycemia 
hospitalizations occurred during 121,262.34 follow-up years (Table 3.1). Among 241,829 adults 
with type 2 diabetes, 553 episodes of hypoglycemia hospitalizations were documented during 
560,685.97 person-years of follow-up among young and middle-aged adults while 3,185 
episodes were documented during 784,131.67 person-years of follow-up among elderly adults. 
 
Type 1 diabetes  
 During the study period, the overall incidence rate was 13.12 hospitalizations for 
hypoglycemia per 1000 person-years (Table 3.1). The incidence rate was 9.57 and 14.80 
hospitalizations for hypoglycemia per 1000 person-years in 1998 and 2013, respectively. Elderly 
adults (≥65 years) and those with the longest duration of diabetes (≥15 years) had higher 
incidence rates of hypoglycemia hospitalizations compared to those with younger age and shorter 
diabetes duration, respectively.  
 From 1998 to 2013, the incidence rate of hypoglycemia hospitalizations increased 3.74% 
(95% CI, 1.70 to 5.83%, P=0.001) annually in all patients with type 1 diabetes (Table 3.2, Figure 
3.2A). This increasing trend was seen in all age groups (Figure 3.2B) and in males and females 
(Figure 3.2C). However, the increasing trend was found only in those with the longest diabetes 
duration; the incidence rate increased 4.97% annually (2.66 to 7.33%, P=0.0004) (Figure 3.2D). 
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Young and middle-aged adults with type 2 diabetes  
 During the study period, the overall incidence rate was 0.99 hospitalizations for 
hypoglycemia per 1000 person-years (Table 3.1). The incidence rate was 0.73 and 1.19 
hospitalizations for hypoglycemia per 1000 person-years in 1998 and 2013, respectively. The 
incidence rate was the highest among insulin users. It was also considerably higher among those 
with long diabetes duration (≥10 years) or older age (45-64 years) compared to those with 
shorter diabetes duration and younger age, respectively.  
 Overall, from 1998 to 2013, the incidence rate increased 4.12% (0.61 to 7.75%, P=0.02) 
annually (Table 3.3, Figure 3.3A). This increasing trend was similar between young (18-44 
years) and middle-aged adults (45-64 years) (Figure 3.3C), between males and females (Figure 
3.3E), and between short duration <10 years and long duration ≥10 years (Figure 3.3G), 
respectively. The incidence rate was increasing among current insulin users; the incidence rate 
increased 5.76% annually (1.11 to 10.64%, P=0.02), but not current sulfonylureas users and 
“other” users (Figure 3.3I).  
 
Elderly adults with type 2 diabetes 
 During the study period, the overall incidence rate was 4.06 hospitalizations for 
hypoglycemia per 1000 person-years (Table 3.1). The incidence rate was 1.12 and 3.52 
hospitalizations for hypoglycemia per 1000 person-years in 1998 and 2013, respectively. The 
incidence rate was high among those who were currently taking insulin, the oldest (≥80 years), 
having the longest duration of diabetes (≥15 years) or currently taking sulfonylureas.  
 Overall, the incidence rate increased 8.59% (5.76 to 11.50%, P<0.0001) annually from 
1998 to 2009, and decreased 8.05% (-14.48 to -1.13%, P=0.03) annually from 2009 to 2013 
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(Table 3.4, Figure 3.3B). This non-linear trend was observed among two subgroups of age (65-
79 years and ≥80 years, Figure 3.3D), and both gender groups (Figure 3.3F). The trend differed 
by diabetes duration (Figure 3.3H). The incidence rate did not change among those with the 
shortest duration (0-4 years). A non-linear trend was seen in the remaining three groups with 
longer duration. The temporal trend differed by current use of anti-diabetic drug(s) (Figure 3.3J). 
There was a linear increasing trend in all groups except users of both insulin and OAD among 
whom a decline in the incidence rate was observed since 2009. Removing current insulin and 
OAD users or two groups with long diabetes duration (10-14 years and ≥15 years) from the 
analyses did not change the overall trend change in year 2009 (data not shown). 
 
Risk factors  
 Adults with type 1 diabetes had higher risk of hypoglycemia hospitalization than adults 
with type 2 diabetes (adjusted IRR 5.61, 95% CI 5.06 to 6.21, Table 3.5). Older age, female 
gender and long diabetes duration ≥15 years were risk factors for hypoglycemia hospitalization 
in adults with type 1 diabetes. In adults with type 2 diabetes, older age, diabetes duration ≥10 
years, current insulin, and sulfonylureas use were risk factors. The risk of hypoglycemia 
hospitalization increased substantially when adults with type 2 diabetes were ≥80 years old, 
current insulin or sulfonylureas users. Current metformin use was associated with lower risk of 
hypoglycemia hospitalization compared to self-management (i.e. currently not taking any anti-
diabetic drug). Compared to the year 1998, the incidence rate of hypoglycemia hospitalizations 
in 2013 increased both in adults with type 1 diabetes (adjusted IRR 1.67, 1.14 to 2.43) and type 2 
diabetes (2.68, 1.71 to 4.20).  
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First hypoglycemia hospitalization only 
 Among 3,266 adults with incident type 1 diabetes, 87 episodes of first hypoglycemia 
hospitalization were recorded during 14,479.82 person-years of follow-up. Among 135,517 
adults with incident type 2 diabetes, 799 episodes of first hypoglycemia hospitalization occurred 
during 752,500.99 person-years of follow-up. In adults with incident type 1 diabetes, the overall 
incidence rate of first hypoglycemia hospitalization was 6.01 hospitalizations per 1000 person-
years and did not change from 1998 to 2013. In young and middle-aged adults with incident type 
2 diabetes, the overall incidence rate was 0.48 hospitalizations/1000 person-years and it 
increased 5.76% (0.72 to 11.05%, P=0.03) annually from 1998 to 2013. In elderly adults with 
incident type 2 diabetes, the overall incidence rate was 1.53 hospitalizations for hypoglycemia 
per 1000 person-years. The incidence rate decreased 6.87% (-11.98 to -1.46%, P=0.02) annually 
since 2009 and no statistically significant trend was seen before 2009. 
 
Discussion 
Principle findings 
 In England, the incidence rate of hypoglycemia hospitalizations increased in adults with 
type 1 diabetes from 1998 to 2013. This increasing trend was seen in all age groups, both 
genders and those with the longest diabetes duration. In young and middle-aged adults with type 
2 diabetes, the incidence rate of hypoglycemia hospitalizations also increased during the entire 
study period. The increasing trend was observed in all subgroups; however, current insulin users 
exhibited the greatest increase. In elderly adults with type 2 diabetes, after a sharp increase in 
years prior to 2009, a decline in the incidence rate of hypoglycemia hospitalizations was 
observed between 2009 and 2013. Nonetheless, the incidence rate in 2013 was still over 2.5 
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times that observed in 1998. This non-linear trend among the elderly with type 2 diabetes was 
seen in two age subgroups, both genders, in patients with ≥5 years of diabetes duration, and 
among current insulin and OAD users. The growing burden of hypoglycemia hospitalizations 
calls for effective approaches to reduce severe hypoglycemia risk in adults with diabetes in 
England.  
 
Type 1 diabetes 
 We are not aware of any investigation of temporal trends in severe hypoglycemia 
incidence specifically among adults with type 1 diabetes in recent decades. Our study provided 
initial evidence of a steady increase in the incidence rate of hypoglycemia hospitalizations in 
adults with type 1 diabetes in England. Major causes of insulin-related hypoglycemia are 
excessive insulin dose, ill-timed dosing or administration of wrong insulin product (e.g., short-, 
intermediate-, or long-acting insulin).13 In adults with type 1 diabetes in England, more attention 
may be given to appropriate meal-planning, correct insulin dosing and adjustment, and use of the 
correct insulin product, in order to reverse the rising trends of hypoglycemia hospitalizations.  
 
Type 2 diabetes 
 In adults with type 2 diabetes, notable differences in temporal trends were found between 
young and middle-aged adults (i.e., linear increasing trend) and elderly adults (i.e., non-linear 
trend), suggesting that age played a crucial role in diabetes management. The increasing trend of 
hypoglycemia hospitalizations in young and middle-aged adults may be driven by the convincing 
microvascular benefits of tight glycemic control32 and diabetes guidelines that individuals with 
short diabetes duration, few comorbidities, and long life expectancy can be treated with more 
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stringent glycemic control.15, 107 The former reason may also explain the rapidly increasing 
incidence rate of hypoglycemia hospitalizations in elderly adults with type 2 diabetes before 
2009. The decline in the incidence rate of hypoglycemia hospitalizations starting in 2009 in 
elderly adults with type 2 diabetes may be driven by physicians who may have recently started to 
treat a proportion of elderly adults with type 2 diabetes with less stringent glycemic control who 
were vulnerable to hypoglycemia. First, well-publicized negative results in 2008-2009 from the 
three trials (ACCORD,40 ADVANCE,41 and VADT42) suggested that elderly adults may not gain 
macrovascular benefits from aggressive glycemic control; rather, intensive therapy was 
associated with increased risk of severe hypoglycemia and may increase mortality. Second, with 
a few exceptions,13, 33 most diabetes guidelines did not emphasize, until very recently, on 
adjusting glycemic targets through evaluating individual’s hypoglycemia risk factors.14, 15, 36 
Subset analyses of ACCORD, ADVANCE and VADT trial data also supported that deciding an 
individual’s HbA1c goal may need to consider this patient’s characteristics such as advanced 
age, long diabetes duration, and advanced atherosclerosis; applying stringent glycemic control to 
all patients with type 2 diabetes was not advisable.108  
 Lipska et al.51 had the same hypothesis that the decreasing trend may be driven by the 
persuasive findings from the three trials.40-42 Lipska et al.’s study was conducted among US 
Medicare beneficiaries ≥65 years old. The hospital admission rate for hypoglycemia decreased 
slightly since 2007 among the entire sample. The decline occurred earlier in 2004 when only 
Medicare beneficiaries with diabetes were analyzed, but diabetes-type specific trend was not 
reported. Only one study assessed long-term severe hypoglycemia trend specifically in adults 
with type 2 diabetes. Chen et al.58 reported an increasing trend of hypoglycemia-related 
emergency department visits from 2000 to 2010 among adults with type 2 diabetes ≥45 years old 
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in Taiwan. The incidence rate increased 4.88 fold (95% CI 3.94 to 6.05) which was similar to 
3.66 fold (2.35 to 5.71) from our study from 1998 to 2009.  
 Subgroup analyses in adults with type 2 diabetes revealed important differences in trends 
by current use of anti-diabetic medications. In young and middle-aged adults with type 2 
diabetes, the incidence rate of hypoglycemia hospitalizations was considerably higher among 
current insulin users than patients who were currently taking other anti-diabetic drug(s). 
Furthermore, the annual increase rate was also the greatest among current insulin users. 
Similarly, in elderly adults with type 2 diabetes, subgroups (e.g., current insulin or sulfonylureas 
users) with markedly high incidence rate of hypoglycemia hospitalizations also had large annual 
increase in trends, contributing to hypoglycemia burden substantially. Although the incidence 
rate of hypoglycemia hospitalizations dropped down in current insulin and OAD users since 
2009, the incidence rate in 2013 was still much higher than that observed in 1998. In addition, 
removing them from analyses did not change the overall non-linear trend (data not shown), 
suggesting that the declining trend was not determined by the subgroup who were currently 
taking insulin and OAD. 
 
Clinical implications 
 Hypoglycemia requiring hospital admission only represents <10% of total severe 
hypoglycemia defined as an event requiring assistance of another person71 and approximately 
25% of emergency department visits for hypoglycemia.52 However, treating hypoglycemic 
episodes resulting in hospital admission is expensive and associated with significant use of 
healthcare resources.98 A CPRD study reported a mean cost of £1034 and a mean hospital stay of 
over 5 days per admission for hypoglycemia; no difference was found between type 1 and type 2 
 33 
 
diabetes.98 Other studies found substantially higher cost per hypoglycemia related 
hospitalization.109 Our data revealed increased incidence rate of hypoglycemia hospitalizations in 
England in adults with type 1 and type 2 diabetes. Reducing the burden of hypoglycemia 
hospitalizations in England is urgent, and medically and economically critical. Of note, although 
the risk of severe hypoglycemia is much lower in type 2 than type 1 diabetes, the number of 
people having type 2 diabetes is about 10 fold more;110 thus, both diabetes types contribute 
significant hypoglycemia burden.  
 Hypoglycemia is a multifactorial problem, but it is preventable in most cases.12 Further, 
preventing hypoglycemia does not mean to sacrifice optimal glycemic control; both can be 
accomplished safely.111 Approaches known to effectively reduce the risk of hypoglycemia 
include patient education, dietary and exercise modifications, medication adjustment, careful 
glucose monitoring by the patient, and conscientious surveillance by the clinician.12 However, 
choosing appropriate strategies for patients with diabetes should consider each individual’s 
specific barriers of hypoglycemia, hypoglycemia risk factors, and long-term health goals.12, 14, 15, 
111  
 
Strengths and limitations 
 Our study provided informative longitudinal trend data following the DCCT study in the 
incidence rate of hypoglycemia hospitalizations in adults with type 1 and type 2 diabetes. 
However, several limitations should be noted. First, misclassification of diabetes and diabetes 
type is a common problem by using electronic health data. We employed conservative 
definitions to differentiate between type 1 and type 2 diabetes compared to other CPRD 
studies,102-104 which may have reduced misclassification error. Second, we only studied 
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hypoglycemia requiring hospital admission. Our data may not be applied to severe hypoglycemia 
not leading to hospitalization. Third, the Quality and Outcomes Framework (QOF) financial 
incentive scheme was introduced in 2004 to the UK primary care clinical systems and the 
diabetes type-specific Read codes were used since 2006 rather than the high level general Read 
code for diabetes.112 They have resulted in more complete data recorded in the CPRD and 
facilitated the distinction between diabetes types. A study reported slightly increased prevalence 
of type 2 diabetes and decreased diagnosis age post the QOF period;113 adjusting these changes 
might even demonstrate larger change in trends, but that is outside the scope of this work. Of 
note, we did not observe any significant change in hypoglycemia trend around 2004-2006. 
Finally, the first recorded diabetes visit date in the CPRD was used as an approximate for 
diabetes diagnosis date which may have underestimated duration of diabetes. 
 
Conclusions 
 In conclusion, hypoglycemia that requires hospitalization has been a rapidly growing 
burden to the healthcare system in England. The incidence rate of hypoglycemia hospitalizations 
increased from 1998 to 2013 in adults with type 1 diabetes, and young and middle-aged adults 
with type 2 diabetes. Although a decline since 2009 was seen in elderly adults with type 2 
diabetes, the incidence rate of hypoglycemia hospitalizations in 2013 was still much higher than 
in 1998. Practical approaches for hypoglycemia management to reverse the increasing trend of 
hypoglycemia hospitalizations in England are critically needed. Studies that are able to 
investigate longitudinal trends of severe hypoglycemia not resulting in hospital admission are 
encouraged.  
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Table 3.1. Observed incidence rates of hypoglycemia hospitalizations per 1000 person years in adults 
with type 1 and type 2 diabetes, in all years combined and by each single year* 
 All years 1998 1999 2000 2001 2002 2003 2004 2005 
Type 1 diabetes          
Overall          
Number of hospitalizations 1,591 38 60 51 66 65 76 97 119 
Incidence rate 13.12 9.57 12.10 8.40 9.80 8.80 9.87 12.25 14.69 
Subgroups          
Age group          
    18-44 years 9.02 5.91 6.33 5.51 6.49 5.63 4.51 10.99 11.09 
    45-64 years 10.94 5.99 11.03 7.28 7.62 7.66 8.96 4.53 11.89 
    65-79 years 21.47 20.13 19.16 15.99 13.00 11.52 19.94 24.30 22.94 
    ≥80 years 48.69 25.29 48.33 15.51 39.91 35.48 35.97 36.33 46.79 
Gender           
    Male 12.05 8.31 10.57 7.14 10.79 8.22 9.61 12.57 12.58 
    Female 14.60 11.27 14.15 10.12 8.45 9.59 10.22 11.80 17.60 
Diabetes duration          
    0-4 years 10.22 9.79 9.21 5.03 7.05 7.13 10.86 8.64 15.17 
    5-9 years 8.79 7.75 7.52 9.56 13.12 4.67 4.75 9.36 11.13 
    10-14 years 11.83 9.30 18.45 8.78 8.60 12.05 10.04 12.55 12.78 
    ≥15 years 15.36 10.26 12.88 9.00 10.17 9.46 10.83 13.94 15.97 
          
Type 2 Diabetes          
<65 years old          
Overall          
Number of hospitalizations 553 7 13 9 9 7 22 28 43 
Incidence rate 0.99 0.73 1.03 0.54 0.44 0.28 0.77 0.86 1.19 
Subgroups          
Age group          
    18-44 years 0.73 0 0.63 0 0.36 0.29 0.77 0.22 0.98 
    45-64 years 1.03 0.84 1.09 0.62 0.46 0.28 0.77 0.97 1.23 
Gender           
    Male 0.94 0.87 1.06 0.60 0.58 0.34 0.59 0.83 0.89 
    Female 1.05 0.53 0.99 0.45 0.25 0.2 1.05 0.92 1.64 
Diabetes duration          
    0-9 years 0.70 0.62 0.57 0.22 0.41 0.24 0.50 0.73 0.79 
    ≥10 years 2.24 1.36 3.52 2.16 0.60 0.51 2.22 1.57 3.34 
Current anti-diabetic drugs          
    Insulin with/without oral  
    drug(s) 
4.33 3.72 4.87 1.22 1.28 1.04 3.07 2.99 4.88 
    Sulfonylureas 
with/without  
    other oral drug(s) 
0.64 0.66 0.68 0.66 0.35 0.31 0.49 0.65 1.08 
    Other§ 0.21 0 0.20 0.15 0.24 0 0.22 0.31 0.11 
          
Type 2 Diabetes 
 ≥65 years old 
         
Overall          
Number of hospitalizations 3,185 15 42 53 88 120 136 158 204 
Incidence rate 4.06 1.12 2.34 2.20 3.00 3.40 3.35 3.45 4.02 
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Subgroups          
Age group          
    65-79 years 2.62 0.79 1.61 1.77 2.10 2.32 1.99 1.86 2.57 
    ≥80 years 7.78 2.16 4.68 3.51 5.65 6.51 7.29 7.98 8.06 
Gender           
    Male 3.81 0.90 2.57 1.99 2.30 3.30 2.95 2.61 3.54 
    Female 4.34 1.33 2.11 2.41 3.71 3.50 3.77 4.33 4.51 
Diabetes duration          
    0-4 years 1.41 0.53 0.95 1.19 1.77 1.96 1.51 1.09 1.71 
    5-9 years 2.57 1.35 2.40 2.50 2.92 3.80 3.01 3.68 3.37 
    10-14 years 5.63 2.70 4.11 3.92 5.19 4.69 5.65 5.21 4.97 
    ≥15 years 11.47 0.66 4.90 2.58 4.49 5.91 7.69 9.02 11.51 
Current anti-diabetic drugs          
    Sulfonylureas only 5.10 1.09 2.34 2.50 2.36 4.76 5.50 4.35 4.33 
    Sulfonylureas + other 
oral  
    drug(s) 
4.63 0.87 1.89 2.67 4.16 3.35 2.94 4.70 5.45 
    Insulin only 19.70 7.20 10.47 7.87 7.63 13.39 16.95 11.08 14.98 
    Insulin + oral drug(s) 12.09 3.63 9.13 5.88 10.36 8.50 7.04 8.69 10.52 
    Other† 0.40 0.23 0.51 0 0.30 0.30 0.30 0.35 0.51 
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   Table 3.1. Continued  
 2006 2007 2008 2009 2010 2011 2012 2013 
Type 1 diabetes         
Overall         
Number of hospitalizations 118 115 132 130 168 112 121 123 
Incidence rate 14.19 13.41 15.20 14.78 19.21 13.10 14.34 14.80 
Subgroups         
Age group         
    18-44 years 9.75 11.55 10.31 9.71 13.31 8.23 11.62 7.68 
    45-64 years 12.46 10.02 9.96 14.86 18.28 10.13 10.99 15.88 
    65-79 years 22.77 18.10 33.74 25.02 24.76 30.64 21.11 22.00 
    ≥80 years 51.72 49.44 64.94 48.34 88.2 49.39 59.73 86.31 
Gender          
    Male 12.67 13.49 13.69 12.24 17.01 12.59 12.03 14.07 
    Female 16.27 13.31 17.29 18.36 22.30 13.81 17.53 15.81 
Diabetes duration         
    0-4 years 11.36 13.20 12.86 6.83 13.77 8.63 10.72 12.45 
    5-9 years 11.12 4.56 9.31 11.80 11.20 6.59 10.97 6.66 
    10-14 years 14.78 12.83 16.29 10.09 11.33 8.71 13.53 10.49 
    ≥15 years 15.54 15.95 16.99 18.39 24.17 16.69 16.09 18.54 
         
Type 2 Diabetes         
<65 years old         
Overall         
Number of hospitalizations 35 33 57 64 63 49 53 61 
Incidence rate 0.88 0.76 1.24 1.33 1.26 0.97 1.05 1.19 
Subgroups         
Age group         
    18-44 years 0.72 0.99 0.63 0.75 1.02 1.00 0.86 0.70 
    45-64 years 0.90 0.73 1.34 1.42 1.29 0.96 1.08 1.27 
Gender          
    Male 0.72 0.86 1.39 1.28 1.27 0.66 1.03 1.18 
    Female 1.11 0.63 1.02 1.39 1.24 1.42 1.08 1.21 
Diabetes duration         
    0-9 years 0.75 0.50 1.00 1.01 0.97 0.73 0.59 0.69 
    ≥10 years 1.56 2.09 2.36 2.74 2.44 1.85 2.57 2.80 
Current anti-diabetic drugs         
    Insulin with/without oral  
    drug(s) 
3.85 3.24 6.00 6.10 5.52 3.61 4.99 6.30 
    Sulfonylureas with/without  
    other oral drug(s) 
0.51 0.48 0.75 0.63 0.87 0.94 0.55 0.44 
    Other§ 0.18 0.17 0.08 0.30 0.25 0.25 0.25 0.27 
         
Type 2 Diabetes 
 ≥65 years old 
        
Overall         
Number of hospitalizations 225 251 327 346 329 316 324 251 
Incidence rate 4.06 4.19 5.17 5.18 4.78 4.51 4.53 3.52 
Subgroups         
Age group         
    65-79 years 2.66 2.89 3.12 3.66 2.91 2.91 2.97 2.25 
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    ≥80 years 7.81 7.59 10.31 8.93 9.24 8.23 8.16 6.45 
Gender          
    Male 3.92 4.24 4.73 4.83 4.16 4.55 4.41 3.57 
    Female 4.21 4.15 5.63 5.56 5.46 4.47 4.67 3.47 
Diabetes duration         
    0-4 years 1.65 1.33 1.40 1.99 1.39 1.10 0.88 1.20 
    5-9 years 2.52 3.02 2.52 3.12 2.43 1.79 1.92 1.57 
    10-14 years 5.43 6.62 8.82 7.06 6.97 5.25 5.05 4.07 
    ≥15 years 12.57 11.36 15.55 13.99 13.25 14.25 13.76 9.31 
Current anti-diabetic drugs         
    Sulfonylureas only 5.74 4.46 7.76 10.68 9.21 6.05 7.71 6.65 
    Sulfonylureas + other oral  
    drug(s) 
4.20 4.81 5.98 5.61 5.19 5.09 4.49 5.33 
    Insulin only 20.02 16.44 25.08 23.80 27.95 23.55 29.25 20.01 
    Insulin + oral drug(s) 12.35 14.41 14.57 16.02 12.21 15.04 13.71 9.19 
    Other† 0.34 0.61 0.59 0.29 0.50 0.40 0.41 0.24 
*Cell counts <5 were not reported with specific values. 
† Included self-management alone (i.e., not currently taking any anti-diabetic drug), oral anti-diabetic 
drug monotherapy (excluding sulfonylureas) or combinations of any anti-diabetic drugs (excluding 
insulin and sulfonylureas). 
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Table 3.2. Trends of hypoglycemia hospitalizations in adults with type 1 diabetes 
 
Period  
Annual percent change 
(95% confidence 
interval) 
P value 
Overall  1998-2013 3.74 (1.70 to 5.83) 0.001 
Age group    
    18-44 years 1998-2013 3.91 (0.42 to 7.52) 0.03 
    45-64 years 1998-2013 5.12 (1.65 to 8.70) 0.01 
    65-79 years 1998-2013 3.48 (0.59 to 6.46) 0.02 
    ≥80 years 1998-2013 6.71 (3.52 to 9.99) 0.0004 
Gender     
    Male 1998-2013 3.36 (1.41 to 5.34) 0.002 
    Female 1998-2013 4.13 (1.43 to 6.89) 0.005 
Diabetes duration    
    0-4 years 1998-2013 2.67 (-0.77 to 6.22) 0.12 
    5-9 years 1998-2013 0.47 (-3.38 to 4.47) 0.80 
    10-14 years 1998-2013 -0.14 (-2.97 to 2.76) 0.92 
    ≥15 years 1998-2013 4.97 (2.66 to 7.33) 0.0004 
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Table 3.3. Trends of hypoglycemia hospitalizations in young and middle-aged adults with type 2 diabetes 
 
Period 
Annual percent change 
(95% confidence 
interval) 
P value  
Overall  1998-2013 4.12 (0.61 to 7.75) 0.02 
Age group    
    18-44 years 1998-2013 4.23 (-0.99 to 9.73) 0.11 
    45-64 years 1998-2013 3.90 (0.18 to 7.76) 0.04 
Gender     
    Male 1998-2013 4.04 (0.04 to 8.21) 0.048 
    Female 1998-2013 3.77 (-1.01 to 8.77) 0.11 
Diabetes duration    
    <10 years  1998-2013 3.53 (-0.98 to 8.25) 0.12 
    ≥10 years 1998-2013 1.82 (-2.22 to 6.04) 0.36 
Current status of anti-diabetic drug use    
    Insulin with/without oral drug (s) 1998-2013 5.76 (1.11 to 10.64) 0.02 
    Sulfonylureas with/without other oral 
drug (s) 
1998-2013 1.42 (-2.87 to 5.90) 
0.50 
    Other* 1998-2013 2.93 (-2.08 to 8.20) 0.23 
* Included self-management alone (i.e., not currently taking any anti-diabetic drug), oral anti-diabetic 
drug monotherapy (excluding sulfonylureas) or combinations of any anti-diabetic drugs (excluding 
insulin and sulfonylureas). 
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Table 3.4. Trends of hypoglycemia hospitalizations in elderly adults with type 2 diabetes* 
 Trend 1  Trend 2  Trend 3 
 Period APC (95% CI)  Period APC (95% CI)  Period APC (95% CI) 
Overall 1998-2009 8.59 (5.76 to 11.50)  2009-2013 -8.05 (-14.48 to -1.13)    
Age group         
    65-79 years 1998-2009 8.28 (4.96 to 11.71)  2009-2013 -8.13 (-16.11 to 0.61)    
    ≥80 years 1998-2008 8.86 (4.02 to 13.93)  2008-2013 -6.41 (-12.45 to 0.06)    
Gender         
    Male 1998-2009 9.00 (5.33 to 12.79)  2009-2013 -6.13 (-14.30 to 2.83)    
    Female 1998-2009 8.18 (4.41 to 12.08)  2009-2013 -9.92 (-18.50 to -0.43)    
Diabetes duration         
    0-4 years 1998-2013 -1.38 (-4.87 to 2.23)       
    5-9 years 1998-2002 24.29 (-5.62 to 63.67)  2002-2013 -6.51 (-9.54 to -3.38)    
    10-14 years 1998-2005 3.12 (-3.19 to 9.85)  2005-2008 17.90 (-9.17 to 53.03)  2008-2013 -12.95 (-17.16 to -8.52) 
    ≥15 years 1998-2008 16.60 (8.21 to 25.64)  2008-2013 -6.32 (-13.67 to 1.66)    
Current anti-diabetic drug use         
    Sulfonylureas only 1998-2013 9.42 (5.11 to 13.91)       
    Sulfonylureas + other OAD 1998-2013 3.74 (0.86 to 6.71)       
    Insulin only 1998-2013 7.62 (4.34 to 11.01)       
    Insulin + OAD 1998-2009 9.50 (3.98 to 15.30)  2009-2013 -8.71 (-19.92 to 4.06)    
    Other* 1998-2013 -0.39 (-5.29 to 4.77)       
Abbreviation: APC, annual percent change; CI, confidence interval; OAD, oral anti-diabetic drug. 
* Included self-management alone (i.e., not currently taking any anti-diabetic drug), oral anti-diabetic drug monotherapy (excluding sulfonylureas) or 
combinations of any anti-diabetic drugs (excluding insulin and sulfonylureas). 
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Table 3.5. Risk factors for hypoglycemia hospitalizations 
 Type 1 diabetes   Type 2 diabetes  
 Crude 
IRR (95% CI) 
Adjusted* 
IRR (95% CI) 
 Crude 
IRR (95% CI) 
Adjusted† 
IRR (95% CI) 
Overall (type 1 versus type 2) 4.58 (3.96 to 5.30) 5.61 (5.06 to 6.21)  Reference Reference 
Year      
    1998 Reference Reference  Reference Reference 
    2009    5.21 (2.86 to 9.48) 3.66 (2.35 to 5.71) 
    2013 1.77 (1.01 to 3.13) 1.67 (1.14 to 2.43)  3.45 (1.89 to 6.30) 2.68 (1.71 to 4.20) 
Age group      
    18-44 years Reference Reference  Reference Reference 
    45-64 years  1.21 (1.02 to 1.42) 1.13 (0.98 to 1.30)  2.01 (1.43 to 2.81) 1.32 (0.99 to 1.75) 
    65-79 years 2.46 (2.08 to 2.91) 2.35 (2.03 to 2.72)  4.53 (3.27 to 6.27) 2.92 (2.22 to 3.84) 
    ≥80 years 5.28 (4.42 to 6.32) 5.21 (4.45 to 6.10)  11.93 (8.61 to 16.54) 8.58 (6.51 to 11.31) 
Gender       
    Male Reference Reference  Reference Reference 
    Female 1.21 (1.01 to 1.46) 1.11 (1.00 to 1.23)  1.04 (0.90 to 1.21) 1.07 (0.99 to 1.16) 
Diabetes duration      
    0-4 years Reference Reference  Reference Reference 
    5-9 years 0.74 (0.55 to 1.01) 0.84 (0.68 to 1.05)  1.24 (1.01 to 1.53) 0.95 (0.84 to 1.08) 
    10-14 years 1.06 (0.80 to 1.42) 1.14 (0.93 to 1.40)  2.12 (1.73 to 2.61) 1.27 (1.12 to 1.43) 
    ≥15 years 1.67 (1.29 to 2.16) 1.31 (1.11 to 1.54)  3.29 (2.69 to 4.04) 1.66 (1.47 to 1.87) 
Current anti-diabetic drugs      
    Self-management alone‡    Reference Reference  
    Metformin only     0.31 (0.21 to 0.45) 0.42 (0.30 to 0.59) 
    Sulfonylureas only    7.87 (6.06 to 10.21) 7.44 (6.03 to 9.17) 
    Sulfonylureas + other oral 
drug(s) 
  
 
6.43 (5.01 to 8.25) 6.59 (5.40 to 8.04) 
    Insulin only    23.45 (18.21 to 30.19) 26.46 (21.53 to 32.51) 
    Insulin + any oral drug(s)    15.73 (12.25 to 20.21) 18.11 (14.80 to 22.17) 
    Other§    0.82 (0.53 to 1.27) 1.36 (0.92 to 2.02) 
Abbreviation: CI, confidence interval; IRR, incidence rate ratio. 
* Adjusted for age (18-44, 45-64, 65-79, ≥80 years), gender (male or female), duration of diabetes (0-4, 5-9, 10-14, ≥15 years) and categorical 
year, as relevant. 
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† Adjusted for age (18-44, 45-64, 65-79, ≥80 years), gender (male or female), duration of diabetes (0-4, 5-9, 10-14, ≥15 years), anti-diabetic drug 
classes as shown in the table and categorical year, as relevant. 
‡ Diabetes managed by lifestyle and not currently taking any anti-diabetic drug. 
§ Oral anti-diabetic drug monotherapy (excluding metformin and sulfonylureas) or combinations of any anti-diabetic drugs (excluding insulin, 
metformin and sulfonylureas). 
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Figure 3.1. Flow chart of identification of type 1 and type 2 diabetes 
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Figure 3.2. Incidence rate of hypoglycemia hospitalizations in adults with type 1 diabetes in the 
total sample (2A), and by age (2B), gender (2C) and diabetes duration (2D) 
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Figure 3.3. Incidence rate of hypoglycemia hospitalizations in young and middle-aged (3A) and 
elderly adults (3B) with type 2 diabetes in the total sample, and by age (3C and 3D), gender (3E 
and 3F), diabetes duration (3G and 3H), and current use of anti-diabetic drugs (3I and 3J) 
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CHAPTER 4. RECENT HBA1C LEVEL AND RISK OF HYPOGLYCEMIA 
HOSPITALIZATION IN ADULTS WITH TYPE 1 AND TYPE 2 DIABETES: A NESTED 
CASE-CONTROL STUDY 
 
Introduction 
 Major diabetes guidelines recommend personalized glycemic management for type 1 
diabetes and type 2 diabetes to balance long-term glycemic benefits and short-term 
hypoglycemia risk.14, 15, 62, 63 Deciding HbA1c treatment target may need to evaluate individual’s 
hypoglycemia risk factors including age, diabetes duration, comorbidities, current use of anti-
diabetic drug(s), life expectancy and history of hypoglycemia. However, the association between 
HbA1c level and risk of severe hypoglycemia remains unclear. In adults with type 1 diabetes, 
earlier studies including the DCCT38 found an inverse association. More recent studies identified 
a U-shape relationship74 or that the previous strong inverse association was considerably 
attenuated with time.71 In adults with type 2 diabetes, aggressive glycemic control increased the 
risk of severe hypoglycemia.114 However, post hoc analyses of the ACCORD trial72 and other 
studies73 found that the risk of severe hypoglycemia was also higher among patients with poor 
glycemic control.  
 For investigating the association between HbA1c level and risk of severe hypoglycemia, 
studies that specifically utilize HbA1c measurements obtained close to the time of severe 
hypoglycemia are rare. Existing studies used “baseline” HbA1c value measured more than three 
months or even years before, or updated average HbA1c,38, 72-75 which may be less predictive of 
the acute event of severe hypoglycemia. Additionally, the majority of investigations did not 
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evaluate possible critical interactions between HbA1c level and important patient characteristics 
that are related to hypoglycemia vulnerability including age, diabetes duration, comorbidities, 
and specific glucose-lowering medications.14, 15, 62, 63, 115 
 To address these gaps, we analyzed linked primary and secondary care data from the 
CPRD and HES from the UK. The primary goal was to determine the association between 
recently measured HbA1c level and risk of hypoglycemia hospitalization in adults with type 1 
and type 2 diabetes. Also, we aimed to determine whether the association was modified by age, 
gender, diabetes duration, weight status, comorbidities, and current anti-diabetic medications.  
 
Methods 
 The study protocol (15_259RA) was approved by the Independent Scientific Advisory 
Committee for Medicines and Healthcare Products Regulatory Agency in the UK.  
 
Data sources  
 Established in 1987, the CPRD is a primary care database that comprises anonymous 
electronic medical records from 684 practices from England, Scotland, Wales and Northern 
Ireland as of January 2015.99 It contained >15 million patient records who were representative of 
age, gender and geographic regions of the UK. The HES stores patient-level information on 
every hospital admission to National Health Service hospitals in England only. The CPRD and 
HES can be linked via a trusted third party.99  384 of 684 CPRD practices that can be linked to 
the HES data between April 1, 1997 and March 31, 2014 comprised our study population. 
Hypoglycemia hospitalizations were extracted from the HES while all other data were obtained 
from the CPRD.  
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Definition of incident type 1 and type 2 diabetes 
 Criteria to identify diabetes cases and type were adopted from relevant CPRD literature 
with modifications to reflect specific differentiation between type 1 and type 2 diabetes.102-104 
Among those with at least one diabetes related code, type 1 diabetes was identified if one of the 
following three criteria was met: (i) ≥1 type 1 code and use of insulin only; (ii) ≥1 type 1 code 
and use of insulin only on the diagnosis date and OAD, if any, was introduced 6 months later; 
(iii) ≥2 insulin prescriptions only and ≥1 unspecified diabetes code. Type 2 diabetes was defined 
as any of the following: (i) ≥2 type 2 codes and 0 type 1 code, regardless of drug use; (ii) ≥1 type 
2 code and 0 type 1 code and OAD only; (iii) ≥1 type 2 code and 0 type 1 code and on OAD and 
insulin, but oral drug prescribed no later than insulin; (iv) ≥2 classes of OAD; (v) ≥2 
prescriptions of a non-insulin non-metformin diabetes related drug only. OAD included 
metformin, sulfonylureas, glinide, thiazolidinediones, DPP-4 inhibitors, SGLT-2 inhibitors, 
GLP-1 agonists, and acarbose. Patients were excluded if they had non-research quality data 
determined by the CPRD team or had a record of secondary diabetes, maturity onset diabetes of 
young, latent autoimmune diabetes in adults, and malnutrition related diabetes. Patients with 
incident type 1 and type 2 diabetes were those with first diabetes visit >365 days after 
registration.102  
 
Follow-up period and definition of hypoglycemia hospitalization  
 The start of follow-up was defined using the latest among the following dates: April 1, 
1997, first diabetes visit date, registration date, the UTS date, or date of turning 18 years old. 
UTS is the date at which the practice data is deemed to be of research quality.99 Follow-up ended 
on the earliest of the following dates: March 31, 2014, death date, transfer-out date, last data 
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collection date, or date of having hypoglycemia (E16.0, E16.1 and E16.2) as primary diagnosis 
for hospitalization. 
 
HbA1c and covariates 
 The HbA1c value most proximal to but within 90 days of hypoglycemia hospitalization 
was the exposure (termed recent HbA1c level). We extracted data on age, gender, smoking 
status, body mass index (BMI), insulin and OAD prescriptions, antihypertensive drug 
prescriptions (including alpha-blockers, beta-blockers, calcium channel blockers, angiotensin II 
receptor blockers, angiotensin-converting enzyme inhibitors, renin inhibitors, diuretics, and 
nitrates), specific diseases that may cause hypoglycemia (including insulinoma, chronic 
pancreatitis, pancreatic adenoma, pituitary adenoma, cystic fibrosis, hypopituitarism, adrenal 
insufficiency, and Addison's disease), and Charlson comorbidity score calculated according to 
the Khan et al.’s approach.116Relevant codes for these variables are available upon request.  
 
Nested-case control design 
 Cases were patients with diabetes who were admitted to hospital due to hypoglycemia. 
For each case, the index date was the date of hospital admission for hypoglycemia. Up to 6 
controls were randomly selected from the case’s risk set after matching. Controls were those who 
had no previous hypoglycemia hospitalization at the risk set date (i.e., index date for controls). 
Cases and matched controls had equal duration of diabetes in days at the respective index date. 
For type 1 adults, cases and controls were matched on age (18-44 or ≥45 years),  gender (male or 
female), weight status (normal/underweight or overweight/obese), Charlson score (≤2 or ≥3), and 
having HbA1c within 90 days of the index date. For type 2 adults, cases and controls were 
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matched on age (18-64, 65-79, ≥80 years), gender, weight status (normal/underweight, 
overweight and obese), Charlson score (≤3, 4-5, ≥6), current insulin use (yes/no), current 
sulphonylureas use (yes/no), and having HbA1c within 90 days of the index date. 
 
Statistical analysis 
 We performed Wilcoxon-Mann Whitney, χ2, and Fisher’s exact tests to compare cases 
and controls. Recent HbA1c level was divided into the following categories: <6%, 6-6.9%, 7.0-
7.9% (reference), 8-8.9%, ≥9%. ORs and 95% CIs were estimated from conditional logistic 
regression models. To minimize residual confounding, we sequentially adjusted for matching 
variables (age, Charlson score, BMI in continuous instead of categorical form), number of years 
of registration, smoking status (non-smoker, current smoker, ex-smoker, and unknown), current 
use of antihypertensive drugs (yes/no), and specific diseases causing hypoglycemia as described 
(yes/no), and current use of metformin (yes/no) or other OAD excluding metformin and 
sulfonylureas (yes/no) (for type 2 diabetes only). The interaction between recent HbA1c level 
and risk of hypoglycemia hospitalization by each of the matching variables was tested by adding 
an interaction term in the fully adjusted model. If P value was <0.1, subgroup analyses were 
performed. In a subset of the study sample with ≥3 HbA1c results prior to hypoglycemia 
hospitalization, we included HbA1c variability (quantified as standard deviation) as an additional 
covariate in the fully adjusted model. All analyses were performed separately for type 1 and type 
2 diabetes using SAS (version 9.4, SAS Institute Inc., Cary, NC).  
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Results 
Characteristics of cases and controls 
 In adults with type 1 diabetes, 143 cases of hypoglycemia hospitalization were matched 
to 817 controls (Table 4.1); cases were more likely to have specific diseases that may cause 
hypoglycemia compared to controls. In adults with type 2 diabetes, 1,007 cases were matched to 
5,842 controls (Table 4.2). Cases had slightly lower HbA1c level, slightly older age and greater 
Charlson score, lower prevalence of current metformin use, GLP-1 agonists use, and other OAD 
use, and higher prevalence of specific diseases compared to controls. All other characteristics 
were similar between cases and controls. 
 
Recent HbA1c level and risk of hypoglycemia hospitalization  
In adults with type 1 diabetes 
 Overall, compared to HbA1c 7-7.9%, higher HbA1c level was associated with lower risk 
of hypoglycemia hospitalization (Figure 4.1); the OR (95% CI) was 0.48 (0.27-0.85) for HbA1c 
8-8.9% and 0.69 (0.42-1.11) for HbA1c ≥9.0%. HbA1c level <7.0% did not increase the risk of 
hypoglycemia hospitalization. The association between HbA1c level and risk of hypoglycemia 
hospitalization was modified by weight status (P=0.04, Figure 4.2). In overweight/obese adults 
with type 1 diabetes, HbA1c <6.0% tended to increase the risk of hypoglycemia hospitalization 
(OR, 2.82;  95% CI, 0.94-8.44), compared to HbA1c 7-7.9%. higher HbA1c level was related to 
lower risk of hypoglycemia hospitalization. HbA1c level was not associated with hypoglycemia 
hospitalization in normal weight or underweight adults with type 1 diabetes. No interaction was 
observed between HbA1c level and risk of hypoglycemia hospitalization by age, gender, diabetes 
duration or comorbidities (P≥0.1); results were not shown. 
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In adults with type 2 diabetes 
 Overall, a U-shape relationship between HbA1c level and risk of hypoglycemia 
hospitalization was identified (Figure 4.1). Specifically, compared to HbA1c 7-7.9%, lower 
HbA1c level was associated with greater risk of hypoglycemia hospitalization; the OR (95% CI) 
was 2.40 (1.87-3.08) for HbA1c <6.0% and 1.54 (1.28-1.86) for HbA1c 6-6.9%. The risk of 
hypoglycemia hospitalization was also higher with HbA1c ≥9.0% (OR, 1.36;  95% CI, 1.09-
1.70).  
 No effect modification for the association between HbA1c level and risk of 
hypoglycemia hospitalization by age, diabetes duration, weight status or comorbidities was 
found (P≥0.1); results were not shown. No clinically meaningful difference was discovered by 
gender, although the P value for interaction was 0.07 (Figure 4.3). Current use of insulin or 
sulfonylureas modified the association (P<0.0001, Figure 4.4). Among adults with T2D who 
were not currently taking insulin and sulfonylureas, HbA1c 8-8.9% and ≥9.0% were associated 
with 88% (OR, 1.88;  95% CI, 1.11-3.17) and 248% (OR, 3.48;  95% CI, 1.98-6.13) higher risk 
of hypoglycemia hospitalization, respectively, compared to HbA1c 7-7.9%. No association was 
found with HbA1c <7.0%. Conversely, among current insulin users or sulfonylureas users, 
HbA1c <7.0% substantially increased the risk of hypoglycemia hospitalization. HbA1c ≥9.0% 
was associated with increased risk in current insulin users, not current sulfonylureas users.   
 
Inclusion of HbA1c variability as an additional covariate 
 Results were not affected by adjusting for HbA1c variability in type 1 diabetes while 
additional adjustment for HbA1c variability in type 2 diabetes attenuated the association between 
recent HbA1c level and risk of hypoglycemia hospitalization for HbA1c ≥9.0% group only, with 
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OR (95% CI) from 1.36 (1.09-1.70) to 1.14 (0.90-1.44) (Table 4.3). The attenuation was mainly 
caused by those not currently taking insulin and sulfonylureas, with OR (95% CI) from 3.48 
(1.98-6.13, Figure 4.4) to 2.01 (1.01-3.98). 84.4% of the type 1 sample and 94.9% of the type 2 
sample were included for this analysis. 
 
Discussion 
 In this investigation using a large cohort of adults with incident type 1 and type 2 diabetes 
from England, the relationship of recent HbA1c level with risk of hypoglycemia hospitalization 
differed markedly between type 1 and type 2 diabetes. For adults with type 1 diabetes, compared 
to HbA1c 7-7.9%, risk of hypoglycemia hospitalization was lower with worse glycemic control 
(HbA1c ≥8.0%) while having better glycemic control (HbA1c <7.0%) did not increase the risk. 
For adults with type 2 diabetes, a U-shape relationship was discovered. Compared to HbA1c 7-
7.9%, better (HbA1c <7.0%) and worst glycemic control (HbA1c ≥9.0%) were associated with 
higher risk of hypoglycemia hospitalization. Further, the association differed by weights status in 
type 1 diabetes and current use of anti-diabetic medications in type 2 diabetes. These results 
supported personalized glycemic targets to reduce hypoglycemia risk. 
 The differences observed in the association of recent HbA1c level with risk of 
hypoglycemia hospitalization between type 1 and type 2 diabetes were likely a result of different 
treatment regimen utilized. Type 1 patients require lifelong exogenous insulin while the majority 
of type 2 patients do not, which also determines higher incidence of severe hypoglycemia in type 
1 diabetes than type 2 diabetes.12 A few studies evaluated the association between HbA1c level 
and risk of severe hypoglycemia in samples involving adults with type 1 diabetes; the findings 
were inconsistent. Earlier studies including the DCCT reported an inverse association,38, 117 or no 
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association.118 A recent study from the DPV Initiative found that the previous strong association 
was substantially attenuated recently and HbA1c became a minor predictor of severe 
hypoglycemia.71 Our population with type 1 diabetes was about 15 years or older on average 
compared to populations examined in these studies.38, 71, 117, 118 However, heterogeneity in age 
may not explain the inconsistencies, because the association between HbA1c level and risk of 
hypoglycemia hospitalization did not differ by age based on our analyses. Notably, the age 
distribution from a recently published study from the T1D Exchange Clinic Registry was similar 
to patients in our study; however, results revealed a U-shape relationship with the lowest risk of 
severe hypoglycemia in HbA1c 7-7.5% group.74   
 The U-shape relationship between recent HbA1c level and risk of hypoglycemia 
hospitalization found in our study in adults with type 2 diabetes was similar to the Lipska et al.’s 
study, but they reported weaker associations.73 Lipska et al. used HbA1c measured between 1 
and 2 years prior to hypoglycemic event as the exposure. They reported that only HbA1c <6.0% 
(OR, 1.25; 95% CI, 0.99-1.57) but not HbA1c 6-6.9% increased the risk of severe hypoglycemia 
compared to HbA1c 7-7.9%. The stronger association identified from our study was possibly due 
to using HbA1c measured in 3 months rather than an earlier time. The former may be more 
closely related to hypoglycemia as an acute complication. In line with the ACCORD study72 and 
the Lipska et al.’s study, we found that poor glycemic control was associated with increased risk 
of hypoglycemia hospitalization. The main previously proposed explanation was that the 
increased risk of severe hypoglycemia was driven by a proportion of patients with type 2 
diabetes who have persistently high HbA1c and are resistant to intensive anti-hyperglycemic 
treatment with stronger drugs or higher doses.38, 72, 73 Another possible explanation may be that 
those with poorest glycemic control had greatest HbA1c variability, because HbA1c variability 
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has been positively associated with risk of severe hypoglycemia.75 In our study, from the lowest 
to highest HbA1c category, the mean HbA1c standard deviation was 0.94, 0.92, 1.01, 1.12, 1.38, 
respectively (P for trend <0.0001; data not shown). Adjusting for HbA1c variability attenuated 
the association considerably in the poorest glycemic control group (HbA1c ≥9.0%). However, 
HbA1c variability did not explain the increased risk of hypoglycemia with low HbA1c (HbA1c 
<7.0%).  
 Interaction analyses from our study revealed critical subgroup findings. For type 1 
diabetes, HbA1c <6.0% potentially increased the risk of hypoglycemia hospitalization only 
among overweight/obese adults. Overweight/obese individuals are likely to be more insulin 
resistant.119 Thus, more intensive insulin regimens may be used, which may increase 
hypoglycemia risk. However, we could not rule out it as a chance finding. For type 2 diabetes, 
the association between recent HbA1c level and risk of hypoglycemia hospitalization differed 
according to current use of insulin or sulfonylureas. The interpretation of the association in 
subgroups by medication should take into account the background incidence of hypoglycemia 
hospitalization within each subgroup. In our data, the incidence of hypoglycemia hospitalization 
per 1000 persons-years was 0.21, 2.47, 6.67 and 7.62, respectively, among those who were not 
currently taking insulin and sulfonylureas, current sulfonylureas users, current insulin users, and 
current both users (data not shown in table). Among adults with type 2 diabetes who were not 
currently taking insulin and sulfonylureas, HbA1c 8-8.9% and ≥9.0% increased the risk of 
hypoglycemia hospitalization by 88% and 248%, respectively. Even after adjusting for HbA1c 
variability, HbA1c ≥9.0% still significantly increased the risk by approximately 100%. This 
implied that more stringent glycemic control may be appropriate for type 2 adults who were self-
managed alone or currently taking anti-diabetic drugs other than insulin and sulfonylureas. 
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Conversely, the risk of hypoglycemia hospitalization was substantially increased with low 
HbA1c level among current insulin or sulfonylureas users who also had considerably high 
background incidence of severe hypoglycemia. This implied that less stringent glycemic control 
may be appropriate for adults with type 2 diabetes who were currently on insulin or 
sulfonylureas, for reducing individual’s risk of severe hypoglycemia and hypoglycemia burden 
to associated healthcare system. 
 Our study was unique because it was the only study using HbA1c measured specifically 
within 3 months of hypoglycemic event. Further, we compared the association of recent HbA1c 
level with risk of hypoglycemia hospitalization between type 1 and type 2 diabetes, both overall 
and by subgroups. However, limitations should be noted. Firstly, the study outcome was a 
selective sample of all hypoglycemia hospitalizations due to restrictions of requiring availability 
of recent HbA1c and case-control matching. The included and excluded hypoglycemia 
hospitalizations were not different in patients with type 1 diabetes (Supplemental Table 4.1), but 
differed in patients with type 2 diabetes (Supplemental Table 4.2). Secondly, misclassification of 
diabetes type may be possible. However, we used conservative definitions to differentiate 
diabetes type and identify incident diabetes compared to other CPRD studies,102, 120, 121 which 
minimized misclassification error. Thirdly, the data completeness in the CPRD and diabetes 
coding methodology were improved due to the introduction of the Quality of Framework 
financial incentive scheme in 2004 and the diabetes type-specific Read codes in 2006.112 
However, the association between recent HbA1c level and risk of hypoglycemia hospitalization 
remained similarly when only investigating the sample from more recent years after 2006 
(P=0.86, data not shown). Fourthly, our study was not designed to study absolute risk 
differences. Translating OR estimates should be in the context of background incidence of severe 
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hypoglycemia in specific population subgroups. Finally, though treatment intensification is an 
important risk factor of severe hypoglycemia and associated with HbA1c,38, 114 it was not 
accounted in the current analyses. 
 In conclusion, the association of recent HbA1c level with risk of hypoglycemia 
hospitalization differed substantially between adults with type 1 and type 2 diabetes. Different 
HbA1c targets may be applied to individuals with diabetes for hypoglycemia management 
according to diabetes type and patient characteristics including weight status in type 1 diabetes 
and current use of insulin or sulfonylureas in type 2 diabetes. Future studies are encouraged that 
have both recently measured HbA1c and detailed information on intensification of treatment 
with time and are also able to study interactions among recent HbA1c level, intensive therapy, 
and patient characteristics.
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Table 4.1. Characteristics of cases with hypoglycemia hospitalization and matched controls in adults with 
type 1 diabetes 
 
Cases 
(N=143) 
% 
Control 
(N=817) 
% 
P value 
Recent HbA1c level 8.26 ± 1.83 8.46 ± 1.76 0.08 
Category of recent HbA1c level   0.07 
    <6% 6.99 5.39  
    6-6.9% 18.18 13.34  
    7-7.9% 26.57 21.30  
    8-8.9% 16.78 26.32  
    ≥9% 31.47 33.66  
Matching variables    
Age, years 51.42 ± 21.35 48.66 ± 19.55 0.16 
Age groups    0.93 
    18-44 years 41.96 42.35  
    ≥45 years 58.04 57.65  
Male  56.64 55.69 0.83 
Duration of diabetes, years 16.64 ± 12.40 15.39 ± 11.07 0.41 
Duration of diabetes category    0.55 
    0-14 years  53.85 56.55  
    ≥15 years 46.15 43.45  
BMI 25.13 ± 4.64 25.51 ± 4.47 0.08 
Weight status    0.74 
    Normal/underweight 53.15 51.65  
    Overweight/obese  46.85 48.35  
Charlson comorbidity score 2.83 ± 2.08 2.55 ± 1.71 0.23 
Comorbidity category    0.77 
    Charlson score ≤2 51.05 52.39  
    Charlson score ≥3 48.95 47.61  
Other confounders    
Number of years of registration  30.30 ± 16.17 28.15 ± 14.84 0.16 
Smoking status   0.26 
    Non-smoker 28.67 31.70  
    Current smoker 25.87 18.73  
    Ex-smoker 16.78 17.50  
    Unknown  28.67 32.07  
Current use of antihypertensive drugsa 46.15 43.57 0.57 
Specific diseases causing hypoglycemiab 4.90 1.71 0.02 
P values <0.05 were in bold. 
Plus/minus values were means and standard deviations. All other values were percentages.  
a Included alpha-blockers, beta-blockers, calcium channel blockers, angiotensin II receptor blockers, 
angiotensin-converting enzyme inhibitors, renin inhibitors, diuretics, and nitrates. 
b Included insulinoma, chronic pancreatitis, pancreatic adenoma, pituitary adenoma, cystic fibrosis, 
hypopituitarism, adrenal insufficiency, and Addison's disease.  
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Table 4.2. Characteristics of cases with hypoglycemia hospitalization and matched controls in adults with 
type 2 diabetes 
 
Cases 
(N=1,007) 
% 
Control 
(N=5,842) 
% 
P value 
Recent HbA1c level 7.52 ± 1.75 7.67 ± 1.52 <0.0001 
Category of recent HbA1c level   <0.0001 
    <6% 13.60 7.39  
    6-6.9% 32.37 27.85  
    7-7.9% 23.34 30.74  
    8-8.9% 13.01 17.63  
    ≥9% 17.68 16.38  
Matching variables    
Age, years 74.74 ± 11.79 74.15 ± 11.32 0.02 
Age groups    0.98 
    18-64 years 17.28 17.36  
    65-79 years 41.91 42.14  
    ≥80 years 40.81 40.50  
Male  54.02 54.25 0.90 
Duration of diabetes, years 11.54 ± 6.68 11.22 ± 6.28 0.36 
Duration of diabetes categories    0.71 
    0-7 years 31.78 32.20  
    8-13 years 35.15 36.03  
    ≥14 years 33.07 31.77  
BMI 28.55 ± 6.71 28.64 ± 6.20 0.25 
Weight status    0.84 
    Normal 31.78 30.90  
    Overweight 34.36 34.53  
    Obese 33.86 34.58  
Current insulin use  41.71 41.00 0.67 
Current sulfonylureas use  41.21 41.25 0.98 
Charlson score 4.31 ± 2.22 4.12 ± 2.23 0.01 
Comorbidity category    0.82 
    Charlson score ≤3 40.42 41.10  
    Charlson score =4,5 31.08 31.34  
    Charlson score ≥6 28.50 27.56  
Other confounders    
Number of years of registration  30.51 ± 17.47 30.17 ± 16.55 0.97 
Smoking status   0.09 
    Non-smoker 33.86 36.49  
    Current smoker 11.52 9.21  
    Ex-smoker 33.37 32.93  
    Unknown  21.25 21.36  
Current metformin use  43.69 56.85 <0.0001 
Current glinide use  0.50 0.65 0.57 
Current thiazolidinediones use  6.06 7.22 0.18 
Current DPP4 inhibitor use  2.78 3.08 0.61 
Current GLP1 agonist use  <0.50 1.01 0.03 
Current acarbose use  0.79 0.77 0.94 
Current other oral drug usea 9.43 12.12 0.01 
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Current use of antihypertensive drugsb 88.08 86.13 0.10 
Specific diseases causing hypoglycemiac 1.79 1.03 0.04 
Abbreviations: DPP4, inhibitors of dipeptidyl peptidase 4; GLP-1; glucagon-like peptide-1 agonists. 
Plus/minus values were means and standard deviations. All other values were percentages.  
The cells with count <5 were not provided with specific value/percentage. 
P values <0.05 were in bold. 
a Included glinide, thiazolidinediones, DPP4 inhibitors, GLP-1 agonists, inhibitors of sodium-glucose co-
transporter 2, and acarbose. 
b Included alpha-blockers, beta-blockers, calcium channel blockers, angiotensin II receptor blockers, 
angiotensin-converting enzyme inhibitors, renin inhibitors, diuretics, and nitrates. 
c Included insulinoma, chronic pancreatitis, pancreatic adenoma, pituitary adenoma, cystic fibrosis, 
hypopituitarism, adrenal insufficiency, and Addison's disease. 
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Table 4.3.  Recent HbA1c level and risk of hypoglycemia hospitalization in adults with type 1 and type 2 diabetes, accounting for HbA1c 
variabilitya 
Values in bold were significant (i.e. P <0.05) 
a Only show fully-adjusted results for subgroup analyses (i.e., with HbA1c standard deviation and number of HbA1c test results included). 
b P value was from the interaction term between HbA1c categorical variable and each of the stratification variables in the fully adjusted model. 
c Model 1 included HbA1c categories, age in years, gender, BMI, Charlson score, duration of diabetes, years of registration, smoking status (non-  
  smoker, current smoker, ex-smoker and unknown), current use of antihypertensive drugs (y/n), and specific diseases (y/n). 
d Model 2: Model 1 + HbA1c standard deviation calculated from all previous HbA1c results prior to hypoglycemia hospitalization, and number of  
 Cases / 
controls 
(N) 
Category of recent HbA1c level, odds ratio (95% confidence interval) P for 
interacti
onb 
 
 
<6% 6-6.9% 7-7.9% 8-8.9% ≥9% 
Type 1 diabetes        
Total        
    Model 1c 143/817 1.01 (0.44-2.32) 1.03 (0.58-1.83) Ref 0.48 (0.27-0.85) 0.69 (0.42-1.11)  
    Model 2d 
Subgroups 
121/689 1.12 (0.44-2.82) 1.36 (0.73-2.54) Ref 0.44 (0.23-0.82) 0.62 (0.35-1.09)  
Overweight/obese       0.16 
    Yes 58/341 3.17 (0.85-11.84) 1.10 (0.43-2.81) Ref 0.31 (0.12-0.76) 0.63 (0.29-1.37)  
    No 63/348 0.33 (0.05-2.03) 1.85 (0.72-4.72) Ref 0.70 (0.27-1.81) 0.73 (0.30-1.77)  
Type 2 diabetes        
Total        
    Model 3e 1,007/5,842 2.40 (1.87-3.08) 1.54 (1.28-1.86) Ref 0.95 (0.75-1.20) 1.36 (1.09-1.70)  
    Model 4f 957/5,542 2.26 (1.73-2.94) 1.53 (1.26-1.86) Ref 0.91 (0.71-1.15) 1.14 (0.90-1.44)  
Subgroups        
Gender       0.12 
    Male 519/3,013 2.07 (1.44-2.98) 1.78 (1.37-2.31) Ref 0.83 (0.60-1.17) 1.06 (0.77-1.47)  
    Female 438/2,529 2.47 (1.67-3.65) 1.26 (0.94-1.69) Ref 0.99 (0.70-1.40) 1.24 (0.89-1.73)  
Status of current insulin 
and sulfonylureas use 
      <0.0001 
    Not on insulin and  
    sulfonylureasg 
222/1,258 1.36 (0.80-2.31) 0.95 (0.62-1.47) Ref 1.36 (0.75-2.49) 2.01 (1.01-3.98)  
    Sulfonylureas use only 326/1,959 3.13 (2.11-4.66) 1.65 (1.22-2.23) Ref 0.67 (0.43-1.06) 0.59 (0.34-1.01)  
    Insulin use only  342/1,980 2.33 (1.31-4.14) 2.00 (1.40-2.85) Ref 0.98 (0.68-1.41) 1.37 (0.99-1.91)  
    Both 67/345 3.29 (0.64-16.88) 2.63 (1.10-6.27) Ref 1.16 (0.46-2.96) 1.33 (0.58-3.06)  
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  HbA1c test results.  
e Model 3 included HbA1c categories, age in years, gender, BMI, Charlson score, duration of diabetes, current insulin user (y/n), current  
  sulfonylureas user (y/n), years of registration, smoking status (non-smoker, current smoker, ex-smoker and unknown), current use of  
  antihypertensive drugs (y/n), specific diseases (y/n), current metformin user (y/n), and current other anti-diabetic drug user (y/n). 
f Model 4: Model 3 + HbA1c standard deviation calculated from all previous HbA1c results prior to hypoglycemia hospitalization, and number of  
  HbA1c test results. 
g Included self-management alone (i.e., by lifestyle only) or currently taking anti-diabetic drug(s) other than insulin and sulfonylureas.  
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Figure 4.1. Association between recent HbA1c level and risk of hypoglycemia hospitalization among adults with type 1 and type 2 
diabetes in the total sample 
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Figure 4.2. Association between recent HbA1c level and risk of hypoglycemia hospitalization among adults with type 1 diabetes, by 
weight status 
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Figure 4.3. Association between recent HbA1c level and risk of hypoglycemia hospitalization among adults with type 2 diabetes, by 
gender 
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Figure 4.4. Association between recent HbA1c level and risk of hypoglycemia hospitalization among adults with type 2 diabetes, by 
anti-diabetic medication 
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Figure legend for Figure 4.1-4.4 
The displayed results were estimated from conditional logistic regression in fully adjusted models (reference: HbA1c 7-7.9%). In type 
1 diabetes, the fully adjusted model included HbA1c categories, age in years, gender, BMI, Charlson score, duration of diabetes, 
number of years of registration, smoking status (non-smoker, current smoker, ex-smoker and unknown), current use of 
antihypertensive drugs (yes/no), and specific diseases causing hypoglycemia (yes/no). In type 2 diabetes, the fully adjusted model 
additionally included current insulin use (yes/no), current sulfonylureas use (yes/no), current metformin use (yes/no), and current use 
of other oral anti-diabetic drug excluding metformin and sulfonylureas (yes/no). For both types in subgroup analyses, the stratification 
variable was not included in the fully adjusted model. P value was from the interaction term between HbA1c categorical variable and 
each of the stratification variables in the fully adjusted model. 
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Supplemental Table 4.1. Characteristics of cases of hypoglycemia hospitalization included and 
excluded in adults with type 1 diabetes  
 
Excluded 
(N=168) 
% 
Included 
(N=143) 
% 
P value 
Age, years 53.83 ± 22.64 51.42 ± 21.35 0.33 
Male  53.57 56.64 0.59 
Duration of diabetes, years 14.84 ± 11.42 16.64 ± 12.40 0.23 
BMI 24.75 ± 5.15 25.13 ± 4.64 0.34 
Charlson score 2.87 ± 2.11 2.83 ± 2.08 0.99 
Years of registration  29.34 ± 15.93 30.30 ± 16.17 0.64 
Smoking status   0.26 
    Non-smoker 31.70 28.67  
    Current smoker 18.73 25.87  
    Ex-smoker 17.50 16.78  
    Unknown  32.07 28.67  
Current use of antihypertensive drugsa 47.62 46.15 0.81 
Specific diseases causing 
hypoglycemiab 
6.55 4.90 0.53 
Plus/minus values were means and standard deviations. All other values were percentages.  
a Included alpha-blockers, beta-blockers, calcium channel blockers, angiotensin II receptor 
blockers, angiotensin-converting enzyme inhibitors, renin inhibitors, diuretics, and nitrates. 
b Include insulinoma, chronic pancreatitis, pancreatic adenoma, pituitary adenoma, cystic 
fibrosis, hypopituitarism, adrenal insufficiency, and Addison's disease. 
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Supplemental Table 4.2. Characteristics of cases of hypoglycemia hospitalization included and 
excluded in adults with type 2 diabetes  
 Excluded 
(N=731) 
% 
Included 
(N=1,007) 
% 
P value 
Age, years 77.89 ± 10.50 74.74 ± 11.79 <0.0001 
Male  45.83 54.02 0.0007 
Duration of diabetes, years 10.98 ± 7.22 11.54 ± 6.68 0.03 
BMI 28.27 ± 9.19 28.55 ± 6.71 0.06 
Charlson score 4.32 ± 2.34 4.31 ± 2.22 0.76 
Years of registration  29.93 ± 16.64 30.51 ± 17.47 0.64 
Smoking status   <0.0001 
    Non-smoker 25.99 33.86  
    Current smoker 8.62 11.52  
    Ex-smoker 24.62 33.37  
    Unknown  40.77 21.25  
Current use of antihypertensive drugsa 85.64 88.08 0.15 
Specific diseases causing 
hypoglycemiab 
2.33 1.79 0.43 
Current insulin use 31.46 41.71 <0.0001 
Current sulfonylureas use 41.72 41.21 0.83 
Current metformin use 29.96 43.69 <0.0001 
Current other oral drug usec 4.38 9.43 <0.0001 
Plus/minus values were means and standard deviations. All other values were percentages.  
P values <0.05 were in bold. 
a Included alpha-blockers, beta-blockers, calcium channel blockers, angiotensin II receptor 
blockers, angiotensin-converting enzyme inhibitors, renin inhibitors, diuretics, and nitrates.  
b Included insulinoma, chronic pancreatitis, pancreatic adenoma, pituitary adenoma, cystic 
fibrosis, hypopituitarism, adrenal insufficiency, and Addison's disease. 
c Included glinide, thiazolidinediones, inhibitors of dipeptidyl peptidase-4, glucagon-like 
peptide-1 agonists, inhibitors of sodium-glucose co-transporter-2, and acarbose.
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CHAPTER 5. USUAL DIETARY INTAKE AND RISK OF NON-SEVERE 
HYPOGLYCEMIA IN ADOLESCENTS WITH TYPE 1 DIABETES 
 
Introduction 
 Hypoglycemia occurs frequently in people with type 1 diabetes with an incidence of over 
1-2 episodes per week per patient.122 Hypoglycemia is preventable and nutrition therapy plays a 
pivotal role in this.76 Current nutrition guidelines are very specific in terms of how to treat 
hypoglycemia when it occurs;30 glucose, sucrose or any form of carbohydrates are to be 
immediately administered. However, information regarding whether or how usual dietary intake 
influences risk of hypoglycemia is limited, particularly for children with diabetes. Medical 
nutrition therapy for adults may not be applicable to children or even conflicts with the evidence 
rising from pediatric populations.76, 82 Further, the literature has primarily focused on 
postprandial glycemic excursions following experimental meals in clinical trial settings, which is 
directly related to acute dietary effect on blood glucose after consuming test meals.82, 89, 123 Yet, 
to our knowledge, no study has examined the effect of usual dietary intake on the risk of 
hypoglycemia measured by CGM in free-living youth with type 1 diabetes, which associates 
typical dietary patterns with day-to-day glycemic control.  
 Youth with type 1 diabetes are particularly vulnerable to hypoglycemia due to 
unpredictable food consumption, erratic activity, and problems with accurate insulin dosing and 
detecting hypoglycemia.30, 62 Their brains are still developing and central nervous systems are 
not yet mature, which put them at high risk of cognitive dysfunction and neurological sequelae of 
hypoglycemia.12, 124 If untreated, mild or moderate hypoglycemia can develop into severe 
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hypoglycemia, resulting in seizure, coma, and death.30 Repeated episodes of severe 
hypoglycemia may even cause permanent damage to the brain with structural changes in the 
white and gray matter of developing brains.31 
 The present study focused on non-severe (i.e., mild or moderate) hypoglycemia, which  
is a low blood glucose event <70 mg/dL but does not require external assistance for recovery. 
Non-severe hypoglycemia accounts for 88-98% of all hypoglycemic events in patients with 
diabetes.25 We aimed to determine the association between usual dietary intake and risk of 
developing non-severe hypoglycemia in a one-week period in a sample of adolescents with type 
1 diabetes who participated in the FL3X randomized clinical trial (ClinicalTrials.gov identifier: 
NCT01286350). The primary goal of the FL3X trial is to improve glycemic control and quality 
of life in adolescents with type 1 diabetes through an evidence-based flexible lifestyle 
intervention.  
 
Methods 
Participants 
 Study participants were a subset of 258 adolescents with type 1 diabetes from the FL3X 
trial who also participated in the ancillary study: Measures of Hypoglycemia and Glycemic 
Variability Using Continuous Glucose Monitoring. Eligible participants were aged 13-16 years at 
study entry who had HbA1c 8-13% and duration of diabetes >1 year. Participants were enrolled 
from two sites: Barbara Davis Center for Childhood Diabetes in Colorado and Cincinnati 
Children’s Hospital Medical Center in Ohio, coordinated by the University of North Carolina 
(UNC) at Chapel Hill. Written informed consent was obtained from parents or legal guardians. 
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The study protocol was approved by the Institutional Review Boards at each participating site. 
For the current study, data were collected during one week period of time at baseline.  
 
Measuring blood glucose using CGM     
 At the baseline visit, the iPro2 CGM system (Medtronic Inc.) with the Enlite sensor was 
inserted into the abdominal subcutaneous adipose tissue. Participants were carefully instructed 
on the use and maintenance of the CGM system and were advised to calibrate the sensor before 
eating and before bed with iPro2 compatible glucometer (OneTouch Ultra2). The Enlite sensor 
measured interstitial glucose level every five minutes within a range 40–400 mg/dL. On the last 
day of the CGM wear week, participants were reminded to send the devices back, using the pre-
paid box/envelope given at the end of the study visit in the first day. The CGM data were 
downloaded with CareLink iPro System and uploaded to the CGM data coordinating center for 
data processing. CGM readings were blinded to study participants. No alarms for hypoglycemia 
or hyperglycemia or any communication from the device were available to participants. 
 
24-hour dietary and physical activity recalls  
 Telephone-administered 24-hour dietary recalls were administered to participants (ideally 
one weekday and one weekend day) to ascertain dietary intake. Interviews were conducted by 
trained and certified interviewers from the UNC NIH/NIDDK Nutrition Obesity Research Center 
(NORC) staff (P30DK056350), using the Nutrient Data System for Research software (NDSR 
Version 2014, Nutrition Coordinating Center, University of Minnesota, Minneapolis, MN) and 
the multiple pass interviewing method.125, 126  
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 The validated Previous Day Physical Activity Recall (PDPAR)127, 128divided the day into 
half-hour time blocks and queried the dominant activity and the approximate intensity of that 
activity for that period. The activity intensity level was grouped into light (slow breathing, little 
or no movement), moderate (normal breathing and some movement), hard (increased breathing 
and moderate movement), and vary hard (hard breathing and quick movement).The PDPAR was 
under the direction of the UNC NORC and administered concurrent with the 24-hour dietary 
recalls.  
 
Other data 
 Self-reported data were collected using standardized questionnaires including age, 
gender, race, highest parental education, duration of diabetes, insulin delivery method, and 
insulin dose. Weight, height, and HbA1c level were measured or assayed according to 
standardized protocols. BMI was calculated as weight (kg)/height squared (m2) and converted to 
a BMI z score using the Center for Disease Control/National Center for Health Statistics 
(CDC/NCHS) 2000 reference curves.129 
  
Statistical analysis  
 No severe hypoglycemic events were reported during the study week. Non-severe 
hypoglycemic events were defined as having CGM readings <70 mg/dL for 10 minutes or 
more.130, 131 They were further categorized into daytime and nocturnal non-severe hypoglycemia. 
This distinction is important because current insulin preparations do not adequately mimic 
normal physiologic patterns of insulin secretion92 and sleep attenuates counter-regulatory 
responses to hypoglycemia.93 Further, dietary intake and exercise94 as two major determinants of 
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blood glucose occur mainly in the daytime. Accordingly, dietary intake is likely to influence 
differently on hypoglycemia risk between day and night. Hypoglycemia that occurred between 
11:00 PM and 7:00 AM was defined as nocturnal hypoglycemia.130 
 Usual daily dietary intake in the study week was averaged from two 24-hour dietary 
recalls. Macronutrients of interest were total carbohydrate, total protein, animal protein, plant 
protein, total fat, saturated fat (SFA), MUFA, PUFA, ratio of MUFA to SFA (MUFA/SFA), and 
ratio of PUFA to SFA (PUFA/SFA). Total fiber, soluble fiber, insoluble fiber, GI, and GL were 
also studied. Patients with no dietary recall, one recall only, and two recalls were compared. 
Further, for those with two dietary recalls, patient characteristics and average daily dietary intake 
were compared among four groups of participants: no hypoglycemia, daytime hypoglycemia 
only, nocturnal hypoglycemia only, and both daytime and nocturnal hypoglycemia. Differences 
were evaluated by the Wilcoxon-Mann-Whitney test for two-group comparison and Kruskal-
Wallis test for comparison of three or four groups.  
 Among those with two dietary recalls, logistic regression models were used to identify 
dietary predictors of daytime hypoglycemia (those with ≥1 episode of daytime hypoglycemia 
versus those without, regardless of nocturnal hypoglycemia), and nocturnal hypoglycemia (those 
with ≥1 episode of nocturnal hypoglycemia versus those without, regardless of daytime 
hypoglycemia). ORs and 95% CIs were estimated. All adjusted models included total calories, 
CGM wear time, and average number of meals per day. Other covariates were also adjusted if 
associated P value was ≤0.2, including age, gender, race (white, non-white), highest parental 
education (four-year college or more, some college or less), duration of diabetes, BMI z score, 
hours with vigorous or moderate physical activity per day, hours with electronic media time or 
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TV time per day, and HbA1c. Finally, insulin delivery method (pump versus multiple daily 
injection) and insulin dose per kilogram were added to the fully adjusted model.  
 
Results 
Patient characteristics 
 Among 258 adolescent participants from the FL3X trial at baseline, 128 had no dietary 
recall; 32 had only one recall while 98 had two recalls (Table 5.1). Participants with no dietary 
recalls had approximately 0.3% higher HbA1c compared to those with two recalls (P=0.06). 
Participants with one recall had higher animal protein intake and slightly lower plant protein 
intake (P=0.04). No difference was found in all other patient characteristics and dietary variables. 
 Among 98 participants who had two 24-hour dietary recalls, 17 of them had no non-
severe hypoglycemia during the study week and 55 developed both daytime and nocturnal non-
severe hypoglycemia (Table 5.2). Participants with non-severe hypoglycemia were not different 
from those without in terms of age, gender, race, diabetes duration, BMI z score, insulin delivery 
method, insulin dose per kilogram, parental education, and physical activity. However, lower 
HbA1c level was seen in participants with non-severe hypoglycemia. Regarding dietary intake, 
descriptively, total fiber including both soluble fiber and insoluble fiber intake were higher in 
participants with non-severe hypoglycemia than those without. Conversely, the GI of the diet 
was higher in participants without non-severe hypoglycemia. Participants with both daytime and 
nocturnal non-severe hypoglycemia had lower MUFA intake compared to participants with only 
daytime or nocturnal non-severe hypoglycemia or without non-severe hypoglycemia.   
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Usual dietary intake and risk of daytime non-severe hypoglycemia  
 Fully adjusted models show that total carbohydrate and the GL were not associated with 
risk of daytime non-severe hypoglycemia (Figure 5.1A, Table 5.3). Every five units higher in the 
GI of the diet was associated with 68% lower risk of daytime non-severe hypoglycemia (OR, 
0.32; 95% CI 0.14-0.73). Intake of soluble fiber, not total fiber, was positively related to the risk 
of daytime non-severe hypoglycemia (Figure 5.1B); the OR (95% CI) for every five grams more 
intake of soluble fiber with risk of daytime non-severe hypoglycemia was 7.86 (0.98-62.19). 
Higher total protein intake by 10 grams per day was associated with higher risk of daytime non-
severe hypoglycemia (OR, 1.47; 95% CI 1.00-2.17; Figure 5.1C). No meaningful difference 
between animal and plant protein was found. However, type of fat was important. Intake of total 
fat or SFA was not related to risk of daytime non-severe hypoglycemia while consumption of 
unsaturated fat was protective (Figure 5.1D). Consuming five grams more MUFA (OR, 0.55; 
95% CI 0.30-1.00) and PUFA (OR, 0.47; 95% CI 0.24-0.90) per day were associated with lower 
risk of daytime non-severe hypoglycemia. An inverse association of MUFA/SFA ratio and 
PUFA/SFA ratio with risk of daytime non-severe hypoglycemia was also found. Adjusting for 
insulin delivery method did not change results. However, after accounting for insulin dose per 
kilogram, all associations disappeared except for PUFA/SFA ratio. 
 
Usual dietary intake and risk of nocturnal non-severe hypoglycemia  
 Total carbohydrate, the GI, and the GL of the diet were not associated with risk of 
nocturnal non-severe hypoglycemia (Table 5.4, Figure 5.2A), according results from the fully 
adjusted model. Similar to daytime non-severe hypoglycemia, soluble fiber intake per 5 grams 
was positively associated with risk of nocturnal non-severe hypoglycemia (OR 8.57, 95% CI 
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1.33-55.07; Figure 5.2B). Higher total protein intake by 10 grams was associated with higher risk 
of nocturnal non-severe hypoglycemia (OR 1.36, 95% CI 0.99-1.86; Figure 5.2C). Dietary fat 
intake was not related to risk of nocturnal non-severe hypoglycemia, including both saturated 
and unsaturated fat (Figure 5.2D). Adjusting for insulin delivery method did not change results. 
After accounting for insulin dose per kilogram, the positive association of soluble fiber and total 
protein with risk of nocturnal non-severe hypoglycemia was no longer statistically significant. 
Unexpectedly, PUFA/SFA ratio was negatively associated with risk of nocturnal non-severe 
hypoglycemia. 
 
Discussion  
 In adolescents with type 1 diabetes, non-severe hypoglycemia was common. Over 80% of 
the study participants developed non-severe hypoglycemia within a week. Higher intake of 
soluble fiber and protein was associated with higher risk of both daytime and nocturnal non-
severe hypoglycemia. The risk of daytime non-severe hypoglycemia was lower with eating 
higher GI diet or with higher MUFA and PUFA intake. Insulin delivery method did not influence 
these associations. After accounting for insulin dose per kilogram, none of these associations 
remained, except for the inverse association with PUFA/SFA ratio. Our findings suggest that 
even though diet-hypoglycemia associations were explained by insulin dose per kilogram, 
hypoglycemia was still very common. How to inject correct dose of insulin at correct time to 
match freely consumed meals to reduce clinically unfavorable events such as hypoglycemia 
remains challenging. 
 Our analyses revealed that total amount of carbohydrate intake was not a predictor of 
non-severe hypoglycemia in adolescents with type 1 diabetes, but quality of carbohydrate 
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(soluble fiber and GI) was related to risk of non-severe hypoglycemia. We found that higher 
intake of soluble fiber, not total fiber, was associated with increased risk of daytime non-severe 
hypoglycemia. Previous literature demonstrated that the reduction of postprandial glucose 
responses after carbohydrate-rich meals was mainly driven by soluble fiber, not insoluble fiber, 
via hindering macronutrient absorption and slowing gastric emptying.132 However, none of the 
published studies in type 1 diabetes populations in the CGM context differentiated the two types 
of fiber. Nonetheless, Maahs et al.84 reported that every one gram increase in total dietary fiber 
intake was associated with 2.4 to 6.5 mg/dL lower postprandial blood glucose up to 4 hours, in 
free-living adolescents with type 1 diabetes. Maahs et al. did not examine the association of 
dietary fiber with risk of hypoglycemia. Lafrance et al.83 found that high-fiber diet decreased 
mean blood glucose, but did not increase the incidence of hypoglycemia. However, Lafrance et 
al. conducted their study in well-controlled patients with type 1 diabetes on intensive insulin 
therapy in a clinical trial setting. Further, the fiber content in the test breakfast of Lafrance et 
al.’s study was approximately 50 grams/1000 kcal, which was substantially higher than that in 
our study. Therefore, their results may not be comparable to our study findings.  
 Another important trait of carbohydrate quality is the GI. An inverse association between 
the GI and risk of daytime non-severe hypoglycemia was identified from our analyses. 
Discerning the independent effect of the GI from fiber is usually difficult,76 because foods rich in 
fiber generally have a low GI, although not all foods with a low GI necessarily have a high fiber 
content.133 However, the negative GI-hypoglycemia relationship remained in our data even after 
adjusting for fiber or other major macronutrients (data not shown). Previous studies consistently 
reported that low-GI foods or diet lowered mean blood glucose concentrations and reduced peak 
glucose excursion compared to high-GI foods or diet in people with type 1 diabetes.83, 85-87 
 81 
 
However, the relationship between the GI and hypoglycemia risk was much less consistent. 
Nansel et al.86 found increased incidence of hypoglycemia with low-GI diet in children with type 
1 diabetes while other studies did not evaluate hypoglycemia risk85 or reported no difference 
between low- and high-GI diet regarding hypoglycemia risk.83, 87 Notably, these studies used 
various definitions of low- and high-GI diet, monitored different length of blood glucose, and 
assigned test meals at different timing. All these may have led to inconsistent findings regarding 
the relationship between the GI and hypoglycemia risk. Nonetheless, existing evidence indicates 
that consistent consumption of a low-GI diet may reduce insulin requirement and improve 
average blood glucose.86, 90 If usual carbohydrate-to-insulin ratio is used, the risk of 
hypoglycemia may be increased with consuming low-GI diet in type 1 diabetes. 
 Our finding that higher protein intake was associated with higher risk of non-severe 
hypoglycemia is in line with the current nutrition recommendations for managing adults with 
diabetes,76 which does not recommend protein for treating or preventing hypoglycemia. Ingested 
protein appears to increase insulin secretion without increasing blood glucose concentrations in 
type 2 diabetes and thus may increase hypoglycemia risk.78, 79 However, the glycemic effect of 
protein is likely to be different between type 1 and type 2 diabetes given the minimal capacity to 
secrete insulin in type 1 diabetes, although residual insulin secretion in youth with type 1 
diabetes may be relevant.80, 81 A review of experimental studies in type 1 diabetes led by Bell et 
al.90 stated that protein tends to increase glucose concentrations in the late postprandial period. 
Also, a randomized trial in youth with type 1 diabetes reported that protein had a protective 
effect on the development of hypoglycemia in the 5-h postprandial period when comparing a diet 
containing 40 grams of protein to the other diet including only 5 grams of protein, holding fat 
and carbohydrate constant.82 This protective effect may not exist in free-living people with type 
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1 diabetes consuming different amount of protein with different amount of other macronutrients 
throughout the day, because the glycemic effect of protein depends on the amount of protein and 
carbohydrate within a meal.90 However, we did not find an interaction between carbohydrate and 
protein in relation to hypoglycemia risk (data not shown). Another reason that may explain the 
positive association between protein intake and risk of non-severe hypoglycemia is that meal-
related insulin dosing may not only consider carbohydrate but also fat/protein.90 Currently, 
specific insulin dosing guidelines account only for carbohydrate,134 yet individual experience 
commonly leads to adjustments for meals high in fat or protein. Thus, some study participants 
may bolus more insulin than needed for high-protein meals, resulting in greater hypoglycemia 
risk.  
 Our data also revealed that fat quality mattered in terms of managing hypoglycemia in 
adolescents with type 1 diabetes. We found that higher MUFA and PUFA intake, not total fat 
and saturated fat, were associated with lower risk of daytime non-severe hypoglycemia. To our 
knowledge, we did not find any diet and CGM study that distinguished fat types. Rather, dietary 
fat as a whole was considered. Studies from Wolpert et al.,135 Smart et al.82 and other 
investigators136, 137 demonstrated that meals containing carbohydrate and that are also high in 
dietary fat can cause sustained late high postprandial blood glucose up to or over 5 hours. The 
relevant mechanisms are delayed gastric emptying, impaired insulin sensitivity, and enhanced 
hepatic glucose production.138 If individuals with type 1 diabetes do not adjust insulin dose for 
dietary fat, they may be more likely to have hyperglycemia instead of hypoglycemia. However, 
these findings from previous studies could not explain the difference between saturated and 
unsaturated fat. In a randomized trial conducted among obese adults with type 2 diabetes, a low 
carbohydrate diet that was high in unsaturated fat and low in saturated fat reduced glucose 
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variability measured by 48-hour CGM. Stabilizing glucose may reflect reduction of both hyper- 
and hypoglycemia. However, adjusting for glucose variability did not change the present results 
(data not shown). Also, the differential effect on insulin resistance between saturated and 
unsaturated fat does not apply here; unsaturated fat causes less profound insulin resistance than 
saturated fat.139 Future work is needed to confirm our findings and propose mechanistic 
explanations. 
 Another notable finding from our study is that dietary intake was a stronger predictor of 
non-severe hypoglycemia in the daytime than nighttime. Similarly, an early large study on type 1 
children by Beregszàszi et al.140 did not find a difference in food consumption in the daytime 
between participants with nocturnal hypoglycemia and those without. The GI-hypoglycemia 
relationship of our study was consistent with the Nansel et al.’s study.86 They also reported no 
differences in the mean blood glucose and hypoglycemia risk in the night between consuming a 
low-GI and a high-GI diet in type 1 children, although the mean blood glucose was lower and 
hypoglycemia risk was higher in the daytime.86 Probably, the main reason is that the failure of 
insulin replacement to mimic normal insulin secretion of pancreas causes a mismatch between 
nighttime insulin requirements and blood glucose, leading to nocturnal hypoglycemia.92, 141 In 
our study, only higher intake of protein or soluble fiber was associated with increased risk of 
nocturnal non-severe hypoglycemia. 
 The dietary associations with hypoglycemia were explained by insulin dose per kilogram 
statistically, but hypoglycemia still occurred in over 80% of our study sample. An important 
missing piece here may be the timing of insulin injection. The injection time depends on blood 
glucose concentration, meal composition, exercise, and type of insulin.142 Different types of 
insulin have disparate pharmacokinetic properties with different onset, peak, and duration, which 
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further complicates insulin dosing.143 We do not know if the high risk of hypoglycemia was in 
part a consequence of incorrect timing of insulin administration since we did not collect relevant 
data. Further, inappropriate insulin dose may still be related. Explaining the identified diet-
hypoglycemia associations is not equal to correct insulin dose delivered. That current guidelines 
rely primarily on carbohydrate counting,134 is not sufficient.90 Optimal actual amount and 
delivery pattern of insulin for meals high in fat or protein or varying in the GI are not yet fully 
understood.  
 Our study is the largest investigation so far that examined the association of usual dietary 
intake with risk of non-severe hypoglycemia in CGM-wearing adolescents with type 1 diabetes. 
However, there are a few important limitations. First, participants with two dietary recalls are a 
selective sample from all participants in the FL3X trial. However, they are not different from the 
FL3X trial participants in all variables except for slightly higher HbA1c (P=0.06). Second, 
participants are not representative of all youth with type 1 diabetes because of requiring HbA1c 
8-13% and duration of diabetes >1 year for inclusion. They are a group of patients with poor 
glycemic control. Third, two days of 24-hour recalls may not capture usual dietary intake, and 
reporting bias may occur. However, participants were interviewed using multi-pass method on 
two unannounced non-consecutive days, which may have reduced the bias. Fourth, although our 
study is the largest study of dietary intake in the CGM setting, the sample size is still not large, 
which precludes assessment of potential interactions among nutrients and effect modifications by 
baseline glycemic status, diabetes duration, and pubertal status. Fifth, we did not consider the 
severity of hypoglycemia which is related to duration of low blood glucose <70 mg/dL and the 
lowest glucose concentration within a hypoglycemic episode. Finally, the definition of nocturnal 
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hypoglycemia is arbitrary, although 11PM-7AM threshold is commonly used in the literature.130, 
144  
 In conclusion, different nutrients from usual dietary intake had different estimated effects 
on the occurrence of non-severe hypoglycemia in free-living adolescents with type 1 diabetes. 
Also, usual dietary intake was differentially associated with risk of non-severe hypoglycemia 
between daytime and nighttime. Our findings suggest that protein intake may be positively 
associated with risk of non-severe hypoglycemia and quality of carbohydrate and fat may be 
critical to reduce risk of non-severe hypoglycemia. Insulin dose per kilogram accounted for the 
dietary effects on hypoglycemia statistically; thus incorrect timing of insulin injection may be a 
key for frequent hypoglycemic events observed in adolescents with type 1 diabetes. Future 
studies that have information on every insulin dosing activity with accurate insulin dose and 
timing recorded are required to better understand the relationship among diet, insulin timing and 
dose, and risk of hypoglycemia. 
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Table 5.1. Patient characteristics according to number of 24-dietary recalls available during the baseline visit 
 No recall 
(N=128) 
one recall 
(N=32) 
Two recalls 
(N=98) 
P* 
Characteristics, % or mean ± SD     
    Age, years 14.99 ± 1.16 14.69 ± 1.02 14.77 ± 1.15 0.26 
    Male 51.56 43.75 51.02 0.72 
    White 84.38 81.25 90.82 0.25 
    Diabetes duration, years  6.57 ± 3.84 5.73 ± 3.34 6.28 ± 3.79 0.53 
    HbA1c, % 9.79 ± 1.28 9.58 ± 0.95 9.40 ± 1.15 0.06 
    BMI z score 0.67 ± 0.96 0.64 ± 0.99 0.64 ± 0.94 0.79 
    On insulin pump 70.08 68.75 72.16 0.91 
    Insulin dose per kilogram, unit 0.98 ± 0.33 0.93 ± 0.33 1.00 ± 0.31 0.90 
    Parental education with 4-year college or 
more 
59.38 53.13 65.31 0.42 
    Exercise level     
        Vigorous, hours/day 0.75 ± 0.76 0.96 ± 1.29 0.89 ± 1.09 0.94 
        Moderate, hours/day 3.17 ± 1.99 2.52 ± 1.77 2.54 ± 1.74 0.69 
        Electronic media time, hours/day 2.79 ± 3.07 1.96 ± 1.60 2.81 ± 2.14 0.19 
        Television, hours/day 2.04 ± 2.03 1.44 ± 1.45 1.80 ± 1.48 0.35 
    Average number of daily meals 
 
4.78 ± 1.43 4.86 ± 1.22 0.67 
Nutrients, % of total energy     
    % calorie from fat  35.21 ± 9.69 35.04 ± 6.04 0.95 
    % calorie from carbohydrate  47.16 ± 9.96 48.74 ± 7.06 0.50 
    % calorie from protein  17.61 ± 4.98 16.20 ± 3.88 0.27 
    % calorie from SFA  12.44 ± 4.15 12.31 ± 3.10 0.83 
    % calorie from MUFA  11.93 ± 4.32 11.89 ± 2.52 0.89 
    % calorie from PUFA  7.71 ± 4.61 7.84 ± 2.61 0.32 
Nutrients, mean ± SD , grams per 1000 kcal     
    Total carbohydrate  120.30 ± 25.67 123.72 ± 18.04 0.54 
    Total fiber  7.83 ± 3.19 8.43 ± 3.42 0.66 
    Soluble fiber  2.68 ± 1.59 2.78 ± 1.06 0.20 
    Insoluble fiber  5.10 ± 2.22 5.59 ± 2.57 0.59 
    Total protein  43.06 ± 11.71 39.89 ± 9.20 0.31 
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    Animal protein  31.00 ± 11.66 25.96 ± 9.32 0.04 
    Plant protein  12.06 ± 4.53 13.93 ± 4.06 0.04 
    Total fat  39.82 ± 10.85 39.88 ± 6.70 0.89 
    SFA  14.07 ± 4.67 14.04 ± 3.58 0.79 
    MUFA  13.48 ± 4.86 13.50 ± 2.80 0.82 
    PUFA  8.73 ± 5.17 8.93 ± 2.97 0.25 
    Glycemic load (glucose reference)  68.44 ± 15.61 69.65 ± 11.70 0.53 
    Glycemic index (glucose reference)  61.31 ± 6.29 60.71 ± 4.28 0.75 
    MUFA/SFA ratio  1.00 ± 0.33 1.00 ± 0.25 0.73 
    PUFA/SFA ratio  0.72 ± 0.58 0.74 ± 0.39 0.12 
Abbreviation: MUFA, monounsaturated fat; PUFA, polyunsaturated fat; SD, standard deviation; SFA, saturated fat 
p values <0.05 were in bold. 
*Based on Wilcoxon-Mann-Whitney test for two groups and Kruskal-Wallis test for three groups  
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Table 5.2. Patient characteristics and average daily dietary intake according to category of non-severe hypoglycemia during one week 
at baseline visit 
 
No 
hypoglycemia 
(N=17) 
Daytime 
hypoglycemia 
only 
(N=15) 
Nocturnal 
hypoglycemia* 
only 
(N=11) 
Daytime and 
nocturnal 
hypoglycemia* 
(N=55) 
P** 
Characteristics, % or mean ± SD      
    Age, years 14.12 ± 1.22 14.33 ± 1.11 14.27 ± 1.01 14.33 ± 1.16 0.90 
    Male 47.06 40.00 63.64 52.73 0.67 
    White 100.0 93.33 90.91 87.27 0.53 
    Diabetes duration, years  6.59 ± 3.71 6.29 ± 3.75 8.01 ± 5.13 5.83 ± 3.52 0.55 
    HbA1c, % 10.21 ± 1.08 9.61 ± 1.07 9.84 ± 1.56 9.01 ± 0.94 0.001 
    BMI z score 1.00 ± 1.03 0.47 ± 1.10 0.40 ± 0.92 0.62 ± 0.87 0.30 
    On insulin pump 64.71 80.00 63.64 74.07 0.69 
    Insulin dose per kg, unit 1.03 ± 0.37 1.06 ± 0.37 0.98 ± 0.26 0.98 ± 0.28 0.97 
    Parental education with 4-year college or 
more 
64.71 60.00 63.64 67.27 0.96 
    Exercise level      
        Vigorous, hours/day 0.91 ± 1.65 0.72 ± 0.82 1.34 ± 1.06 0.83 ± 0.95 0.24 
        Moderate, hours/day 2.25 ± 2.00 2.20 ± 1.70 3.14 ± 1.70 2.60 ± 1.69 0.24 
        Electronic media time, hours/day 2.91 ± 2.14 2.43 ± 1.30 2.80 ± 2.01 2.89 ± 2.37 0.99 
        Television, hours/day 1.31 ± 1.01 2.12 ± 1.13 1.66 ± 1.11 1.90 ± 1.72 0.36 
    Average number of daily meals 4.71 ± 1.23 4.73 ± 1.56 5.55 ± 1.08 4.81 ± 1.12 0.12 
Nutrients, % of total energy      
    % calorie from fat 36.87 ± 6.82 34.99 ± 6.27 37.46 ± 6.56 34.01 ± 5.50 0.07 
    % calorie from carbohydrate 47.79 ± 8.80 49.20 ± 8.76 48.07 ± 8.64 49.05 ± 5.69 0.51 
    % calorie from protein 15.30 ± 4.41 15.85 ± 3.82 14.43 ± 3.34 16.93 ± 3.74 0.16 
    % calorie from SFA 12.33 ± 3.61 12.30 ± 3.19 12.49 ± 3.02 12.27 ± 3.02 0.95 
    % calorie from MUFA 12.67 ± 2.25 11.71 ± 2.36 13.14 ± 2.57 11.45 ± 2.55 0.04 
    % calorie from PUFA 8.91 ± 2.90 7.95 ± 2.51 8.93 ± 2.84 7.25 ± 2.38 0.07 
Nutrients, mean ± SD , grams per 1000 kcal      
    Total carbohydrate 120.66 ± 
22.72 
123.51 ± 22.01 123.00 ± 21.07 124.86 ± 14.81 0.49 
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    Total fiber 6.47 ± 1.78 7.98 ± 2.65 8.62 ± 2.62 9.12 ± 3.90 0.01 
    Soluble fiber 2.13 ± 0.50 2.77 ± 1.12 2.70 ± 0.73 2.99 ± 1.16 0.006 
    Insoluble fiber 4.27 ± 1.41 5.18 ± 1.76 5.89 ± 2.02 6.06 ± 2.97 0.04 
    Total protein 37.50 ± 10.10 39.26 ± 8.76 36.96 ± 7.77 41.59 ± 9.09 0.17 
    Animal protein 24.81 ± 11.51 26.53 ± 9.06 23.23 ± 8.30 26.71 ± 8.95 0.65 
    Plant protein 12.68 ± 3.06 12.72 ± 2.48 12.73 ± 3.81 14.89 ± 4.52 0.09 
    Total fat 41.87 ± 7.79 40.09 ± 6.53 42.39 ± 6.72 38.70 ± 6.27 0.09 
    SFA 14.00 ± 4.35 14.18 ± 3.68 14.04 ± 3.41 14.01 ± 3.43 0.93 
    MUFA 14.37 ± 2.61 13.36 ± 2.56 14.96 ± 2.64 12.97 ± 2.85 0.03 
    PUFA 10.16 ± 3.40 9.05 ± 2.84 10.14 ± 2.92 8.28 ± 2.75 0.06 
    Glycemic load (glucose reference) 72.24 ± 15.44 68.03 ± 13.37 69.48 ± 11.77 69.33 ± 10.01 0.84 
    Glycemic index (glucose reference) 63.48 ± 3.69 59.32 ± 3.61 61.33 ± 4.57 60.10 ± 4.27 0.01 
    MUFA/SFA ratio 1.07 ± 0.22 1.00 ± 0.31 1.11 ± 0.27 0.96 ± 0.24 0.08 
    PUFA/SFA ratio 0.86 ± 0.43 0.75 ± 0.32 0.83 ± 0.31 0.69 ± 0.41 0.20 
Abbreviation: MUFA, monounsaturated fat; PUFA, polyunsaturated fat; SD, standard deviation; SFA, saturated fat 
p values <0.05 were in bold. 
*10 min or more with low blood glucose <70 mg/dL between 11PM and 7AM defined nocturnal hypoglycemia  
**P value from Kruskal-Wallis test. 
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Table 5.3. Usual dietary intake and risk of daytime non-severe hypoglycemia* 
 Model 1 Model 2 Model 3 Model 4 Model 5 
Nutrients 
Unadjusted Partially adjusted Fully adjusted 
Adding insulin 
delivery method 
Further adding 
insulin dose/kg 
Carbohydrate      
    Total carbohydrate, per 10 
grams 
0.98 (0.93-1.03) 1.11 (0.95-1.29) 1.03 (0.86-1.22) 1.03 (0.86-1.22) 0.93 (0.75-1.17) 
    Total fiber, per 5 grams 1.07 (0.74-1.53) 1.48 (0.87-2.53) 1.71 (0.86-3.40) 1.73 (0.87-3.47) 1.26 (0.54-2.90) 
    Soluble fiber. per 5 grams 1.68 (0.53-5.33) 8.44 (1.34-53.28) 7.86 (0.98-63.19) 8.07 (0.98-66.51) 5.02 (0.29-87.96) 
    Insoluble fiber, per 5 grams 1.03 (0.62-1.69) 1.37 (0.69-2.71) 1.74 (0.68-4.47) 1.76 (0.68-4.57) 1.09 (0.36-3.29) 
    Glycemic index, per 5 score 0.44 (0.24-0.79) 0.40 (0.21-0.76) 0.32 (0.14-0.73) 0.32 (0.14-0.74) 0.35 (0.12-1.04) 
    Glycemic load, per 10 grams 0.52 (0.22-1.23) 0.69 (0.08-6.19) 0.23 (0.02-3.49) 0.24 (0.02-3.53) 0.04 (<0.001-2.50) 
Protein      
    Total protein, per 10 grams 0.99 (0.85-1.16) 1.23 (0.91-1.65) 1.47 (1.00-2.17) 1.47 (1.00-2.17) 1.34 (0.85-2.12) 
    Animal protein, per 10 grams 0.99 (0.82-1.20) 1.11 (0.84-1.47) 1.27 (0.91-1.79) 1.28 (0.91-1.80) 1.26 (0.83-1.92) 
    Plant protein, per 10 grams 0.96 (0.61-1.49) 1.65 (0.78-3.49) 1.86 (0.78-4.42) 1.87 (0.79-4.47) 1.35 (0.40-4.51) 
Fat      
    Total fat, per 5 grams 0.94 (0.88-1.00) 0.81 (0.66-0.99) 0.84 (0.67-1.06) 0.84 (0.67-1.06) 1.00 (0.76-1.30) 
    SFA, per 5 grams 0.93 (0.79-1.09) 1.05 (0.76-1.46) 1.20 (0.80-1.80) 1.20 (0.80-1.81) 1.79 (0.92, 3.48) 
    MUFA, per 5 grams 0.80 (0.67-0.97) 0.54 (0.33-0.88) 0.55 (0.30-1.00) 0.55 (0.30-1.00) 0.93 (0.47-1.83) 
    PUFA, per 5 grams 0.68 (0.51-0.92) 0.55 (0.34-0.90) 0.47 (0.24-0.90) 0.47 (0.24-0.90) 0.55 (0.27-1.11) 
    MUFA/SFA ratio, per 1 unit 0.16 (0.03-0.94) 0.17 (0.03-1.04) 0.07 (0.01-0.83) 0.07 (0.006, 0.83) 0.16 (0.008-3.29) 
    PUFA/SFA ratio, per 1 unit 0.41 (0.13-1.26) 0.39 (0.13-1.20) 0.19 (0.05-0.78) 0.19 (0.05-0.78) 0.15 (0.03, 0.86) 
Abbreviation. MUFA, monounsaturated fat; PUFA, polyunsaturated fat; SFA, saturated fat. 
*Significance results (<0.05) were highlighted in bold, but p value for total protein in the fully adjusted model (Model 3) was 0.0503. 
Model 1. Unadjusted. 
Model 2. Adjusted for CGM wear time, total energy intake per day, and average number of meals per day. 
Model 3. Model 2 +  diabetes duration, HbA1c, daily electronic media time in hours, and TV time in hours. 
Model 4. Model 3 + insulin delivery method (pump versus multiple daily injection). 
Model 5. Model 4 + insulin dose per kilogram. 
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Table 5.4. Usual dietary intake and risk of nocturnal non-severe hypoglycemia* 
 Model 1 Model 2 Model 3 Model 4 Model 5 
Nutrients 
Unadjusted Partially adjusted Fully adjusted 
Adding insulin 
delivery method 
Further adding 
insulin dose/kg 
Carbohydrate      
    Total carbohydrate, per 10 
grams 
0.96 (0.92-1.01) 0.98 (0.86-1.13) 0.95 (0.82-1.11) 0.94 (0.80-1.10) 0.92 (0.76-1.13) 
    Total fiber, per 5 grams 1.11 (0.78-1.58) 1.68 (0.98-2.85) 1.73 (0.97-3.08) 1.58 (0.88-2.86) 1.38 (0.67-2.82) 
    Soluble fiber. per 5 grams 1.47 (0.49-4.38) 8.43 (1.44-49.46) 8.57 (1.33-55.07) 7.08 (1.08-46.57) 5.06 (0.51-50.40) 
    Insoluble fiber, per 5 grams 1.14 (0.70-1.85) 1.69 (0.85-3.34) 1.76 (0.82-3.75) 1.56 (0.72-3.38) 1.27 (0.51-3.18) 
    Glycemic index, per 5 score 0.71 (0.42-1.18) 0.79 (0.46-1.36) 0.83 (0.47-1.46) 0.86 (0.48-1.53) 0.57 (0.26-1.24) 
    Glycemic load, per 10 grams 0.45 (0.19-1.03) 0.37 (0.04-3.07) 0.27 (0.03-2.69) 0.27 (0.03-2.93) 0.10 (0.004-2.66) 
Protein      
    Total protein, per 10 grams 0.96 (0.82-1.11) 1.24 (0.93-1.66) 1.36 (0.99-1.86) 1.38 (0.99-1.91) 1.35 (0.92-1.98) 
    Animal protein, per 10 grams 0.95 (0.79-1.13) 1.12 (0.86-1.47) 1.21 (0.91-1.60) 1.23 (0.92-1.64) 1.21 (0.86-1.70) 
    Plant protein, per 10 grams 0.93 (0.61-1.43) 1.65 (0.81-3.39) 1.66 (0.77-3.54) 1.56 (0.71-3.45) 1.66 (0.59-4.63) 
Fat      
    Total fat, per 5 grams 0.94 (0.88-1.00) 0.96 (0.80-1.14) 0.97 (0.79-1.18) 0.98 (0.79-1.20) 1.00 (0.78-1.28) 
    SFA, per 5 grams 0.91 (0.78-1.07) 1.12 (0.81-1.53) 1.18 (0.84-1.67) 1.17 (0.82-1.67) 1.60 (0.93-2.74) 
    MUFA, per 5 grams 0.85 (0.71-1.02) 0.95 (0.62-1.45) 0.93 (0.57-1.52) 1.00 (0.60-1.68) 1.17 (0.62-2.18) 
    PUFA, per 5 grams 0.72 (0.55-0.95) 0.71 (0.46-1.10) 0.70 (0.44-1.13) 0.71 (0.44-1.16) 0.51 (0.26-1.00) 
    MUFA/SFA ratio, per 1 unit 0.45 (0.09-2.33) 0.41 (0.07-2.33) 0.30 (0.05-1.96) 0.38 (0.06-2.57) 0.18 (0.02-1.89) 
    PUFA/SFA ratio, per 1 unit 0.56 (0.19-1.64) 0.51 (0.17-1.54) 0.42 (0.13-1.39) 0.41 (0.12-1.38) 0.20 (0.04-0.90) 
Abbreviation. MUFA, monounsaturated fat; PUFA, polyunsaturated fat; SFA, saturated fat. 
*Significance results (<0.05) were highlighted in bold. 
Model 1. Unadjusted. 
Model 2. Adjusted for CGM wear time, total energy intake per day, and average number of meals per day. 
Model 3. Model 2 +  diabetes duration, HbA1c, daily electronic media time in hours, and TV time in hours. 
Model 4. Model 3 + insulin delivery method (pump versus multiple daily injection). 
Model 5. Model 4 + insulin dose per kilogram. 
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Figure 5.1. Daily macronutrients intake and daytime non-severe hypoglycemia 
 
SFA, saturated fat; MUFA, monounsaturated fat; PUFA, polyunsaturated fat. The models were adjusted for CGM wear time, total 
daily energy intake, average number of daily meals, diabetes duration, HbA1c, daily electronic media and TV time. All associations 
disappeared after additionally adjusting for insulin dose per kilogram except PUFA/SFA ratio; please refer to Table 5.3 for details. 
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Figure 5.2. Daily macronutrients intake and nocturnal non-severe hypoglycemia 
 
SFA, saturated fat; MUFA, monounsaturated fat; PUFA, polyunsaturated fat. The models were adjusted for CGM wear time, total 
daily energy intake, average number of meals per day, diabetes duration, HbA1c, daily electronic media and TV time. All associations 
did not exist after additionally adjusting for insulin dosing except for PUFA/SFA ratio; please refer to Table 5.4 for details.
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CHAPTER 6. SYNTHESIS 
Overview of findings 
 Our project improves current understanding on hypoglycemia from population, 
individual, and behavioral perspectives (Figure 6). For the first time, we reported long-term 
trends of severe hypoglycemia specifically in adults with type 1 diabetes and compared trends 
between adults with type 1 and type 2 diabetes from the same source population, covering almost 
two decades. We are also the first study to investigate HbA1c-hypoglycemia relationship using 
recently measured HbA1c within 3 months of hypoglycemic events. Importantly, we assessed 
whether the HbA1c-hypoglycemia association was modified by diabetes type, and a range of 
hypoglycemia risk factors, which has never been done before. Our study also provided initial 
data to explain the relationship between usual dietary intake and risk of hypoglycemia in youth 
with type 1 diabetes. The major findings from each aim are summarized here. At population 
level explored in Aim 1, we found a rapidly growing burden of hypoglycemia hospitalizations 
both in adults with type 1 and type 2 diabetes in England, which urgently calls for effective 
approaches to reduce hypoglycemia in diabetes. Aims 2 and 3 explored two exposures that may 
ultimately be useful to reduce or prevent hypoglycemia. In Aim 2, we found that recent HbA1c 
level was associated with risk of hypoglycemia hospitalization differently by diabetes type and 
other factors like BMI in type 1 diabetes and current anti-diabetic medication use in type 2 
diabetes. Our analyses suggested applying individualized glycemic targets to reduce 
hypoglycemia risk. Finally in Aim 3, we found that the associations between usual dietary intake 
and risk of non-severe hypoglycemia were accounted by insulin dose per kilogram, but 
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Figure 6. Dissertation overview  
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hypoglycemia occurred in >80% of the study sample who were a selective group of adolescents 
with type 1 diabetes. Injecting insulin at an inappropriate time may be a key reason for the 
frequent hypoglycemic events seen in our study participants. 
 We expected a reduced risk of hypoglycemia in recent years due to the following three 
trends in diabetes management: i) New diabetes drugs including DPP-4 inhibitors, GLP-1 
agonists, and SGLT-2 inhibitors have become available and they do not induce hypoglycemia by 
themselves, unless they are used together with other hypoglycemia-inducing drugs such as 
insulin or sulfonylureas;46, 145 ii) Recent shift in diabetes guidelines towards recommending 
individualized glycemic targets rather than achieving near normal glycemic control in all patients 
with diabetes would likely to reduce hypoglycemia;14, 15, 62, 63 iii) new technologies such CGM 
and insulin pump may help patients with diabetes, in particular type 1 diabetes, to better manage 
blood glucose.47, 48 However, our data and other recently published studies show that the risk of 
hypoglycemia has been increasing.51, 55, 58 We found that the incidence of hypoglycemia 
hospitalizations increased in adults with type 1 diabetes and in young and middle-aged adults 
with type 2 diabetes between 1998 and 2013. A decline in the incidence of hypoglycemia 
hospitalizations was only seen in elderly adults with type 2 diabetes since 2009 which is 
coincident with recent changes in diabetes guidelines and the publication of ACCORD,40 
VADT,42 and ADVANCE41 trials in 2008-2009 in the New England Journal of Medicine. 
Although severe hypoglycemia can be fatal and is associated with various poor health 
outcomes,19-23 The primary cause of death in people with either type 1 or type 2 diabetes is 
cardiovascular disease, and cardiovascular disease accounts for the greatest component of health 
care expenditures in diabetes.146-148 Also, microvascular complications can have devastating 
impact on quality of life in patients with diabetes and diabetes is a major cause of blindness, 
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renal failure, and amputation.149 Maintaining HbA1c level to a near-normal target is currently the 
most effective approach to delay the onset and progression of all microvascular complications 
(i.e., retinopathy, nephropathy, and neuropathy) and to reduce risk of cardiovascular disease and 
mortality in diabetes.150 Accordingly, achieving near normal glycemic control , even with 
intensive therapy, may still be the common practice and the priority. In elderly adults with type 2 
diabetes who usually have multiple comorbidities, long diabetes duration, and limited life 
expectancy, recently, the guidelines started to recommended less stringent glycemic control. 
Together with the persuasive trials reporting no additional macrovascular benefits by achieving 
HbA1c lower than the general recommended targets in type 2 diabetes,40-42 physicians may have 
recently started to treat a proportion of elderly adults with type 2 diabetes with high 
hypoglycemia risk with less aggressive therapy. 14, 15, 107 Nonetheless, the risk of hypoglycemia 
hospitalizations was still high in elderly adults in our study. How to balance between hyper- and 
hypoglycemia risk is still a major challenge in diabetes.  
 Setting an appropriate HbA1c target helps reduce risk of severe hypoglycemia in 
individuals with diabetes and ultimately reduces hypoglycemia burden to associated healthcare 
systems.14, 15, 62, 63  We found that, in adults with type 1 diabetes, compared to HbA1c 7-7.9%, 
higher HbA1c was associated with lower risk of hypoglycemia hospitalization while lower 
HbA1c was not related to increased hypoglycemia risk. However, in overweight/obese type 1 
patients, low HbA1c <6.0% tended to increase the risk of hypoglycemia hospitalization. In adults 
with type 2 diabetes, the HbA1c-hypoglycemia relationship was U-shaped. Compared to HbA1c 
7-7.9%, both lower and higher HbA1c (≥9.0%) were associated with higher risk of 
hypoglycemia hospitalization. Current use of insulin or sulfonylureas modified the association. 
Higher HbA1c (≥8.0%) was associated with increased risk of hypoglycemia hospitalization in 
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adults with type 2 diabetes who were not currently taking insulin or sulfonylureas. Conversely, 
among current insulin or sulfonylureas users, lower HbA1c (<7.0%) was associated with higher 
risk of hypoglycemia hospitalization. These findings supported individualized glycemic 
management according to current diabetes guidelines14, 15, 62, 63 
 Nutrition plays a key role in diabetes management including preventing hypoglycemia.76 
In type 1 diabetes, correctly matching insulin dose to food intake is a key to reduce risk of 
hypoglycemia.90 Our analyses confirmed this. In a group of adolescents with type 1 diabetes, we 
found that the associations between usual dietary intake and risk of non-severe hypoglycemia 
were fully accounted by insulin dose per kilogram. Of note, the insulin dose used here is the 
usual daily insulin dose based on self-report, not necessarily the insulin dose administered on the 
same day of the dietary recall. Current guidelines for insulin dosing primarily based on 
carbohydrate counting are not sufficient to control risk of hypoglycemia to a low level in most 
people with type 1 diabetes.134 Over 80% of our study participants developed non-severe 
hypoglycemia within a week, although they were patients with poor glycemic control with 
HbA1c 8-13% at study entry. Since insulin dose per kilogram explained diet-hypoglycemia 
associations, two other important aspects that were not considered in our analyses are timing of 
insulin injection and insulin type. The injection time depends on blood glucose concentration, 
meal composition, exercise, and type of insulin.142 Different types of insulin have disparate 
pharmacokinetic properties with different onset, peak, and duration, which further complicates 
insulin dosing.143 The high risk of hypoglycemia may be the consequence of incorrect timing of 
insulin injection and mismatch between insulin pharmacodynamics and postprandial glucose 
excursions. Although insulin dose per kilogram could explain the diet-hypoglycemia 
associations, this does not mean that optimal insulin dose was administered by our participants. 
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Insulin dosing need to consider dietary protein, fat, and possibly the GI. 82, 90, 135 We found that 
different nutrients (particularly soluble fiber and unsaturated fat) from usual dietary intake had 
different effects on the occurrence of non-severe hypoglycemia and the effect of dietary intake 
on risk of non-severe hypoglycemia was different between daytime and nighttime. These 
findings may contribute to refinement of insulin dosing algorithms in the future. Further, barriers 
to diabetes self-management also need to be addressed in order for participants to adhere to the 
recommended insulin therapy, which is also the main goal of the FL3X trial. 
 
Limitations 
 This research has a number of limitations. The primary limitation is that the selection of 
study participants by pre-defined inclusion criteria may bias the findings or influence the 
generalizability of the results. A couple of methodological limitations should be noted. For 
example, nested-case control design cannot directly study absolute risk differences and true usual 
dietary intake may not be captured by two 24-hour recalls. Also, confounding bias may be likely 
due to the missing data on relevant confounders. Further, a few important analyses could not be 
done due to the insufficient sample size. For example, we are unable to study both the first 
episode and all episodes of hypoglycemia. Important subgroup analyses or effect modification 
analyses could not be done. Finally, limitations associated with using longitudinal electronic 
medical record data need to be discussed.  
 
Selection of study population 
 Selection of study population exists in all aims which may influence the generalizability 
of the findings or may bias the results. In Aim 1, the longitudinal trends of hypoglycemia 
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hospitalizations in adults with type 1 or type 2 diabetes estimated from our study may only be 
applicable to adult populations with diabetes in England, not the entire UK. Not all CPRD 
practices are linked to the HES. The CPRD includes practices from England, Scotland, Wales, 
and Northern Ireland. However, the HES stores patient-level data from all people who have been 
admitted to National Health Service hospitals in England only.99 By design for Aim 2, the study 
sample was limited to only those who had an HbA1c result measured within 90 days of the index 
date for hypoglycemia cases and controls, based on nested case-control design. This restriction 
excluded 54% of hypoglycemia hospitalization cases in type 1 diabetes and 42% in type 2 
diabetes, which may have resulted in selection bias. In type 1 diabetes, the included and excluded 
cases were not statistically different (Supplemental Table 4.1). In type 2 diabetes, the excluded 
cases were different from the included cases who were slightly younger, more likely on insulin 
and metformin, had higher proportion of males and slightly longer duration of diabetes 
(Supplemental Table 4.2). The selection bias may have influenced the results in type 2 diabetes. 
However, the associations in type 2 diabetes are consistent with literature.72, 73 Further, additional 
analyses indicate that the association between recent HbA1c level and risk of hypoglycemia 
hospitalization in type 2 adults is robust. The magnitude and shape of the association remained 
when using first episode of hypoglycemia hospitalization as the outcome, which results in more 
loss of study sample (Table 6.1). In Aim 3, the adolescents with type 1 diabetes included in the 
final analyses (N=98) only account for 38% of the total 258 participants who were enrolled into 
the FL3X randomized clinical trial. However, the data for current dietary analyses were from an 
ancillary study of the FL3X trial at baseline in which only 130 participants were administered 
24-hour dietary recall. In fact, the demographics and clinical characteristics were not different 
between final analytical sample (N=98) and FL3X trial participants (N=258), including age,  
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Table 6.1. Stratification analyses for evaluating association between HbA1c levels and risk of hypoglycemia in the fully adjusted model 
 HbA1c, odds ratio (95% confidence interval) P for 
interaction*  <6% 6-6.9% 7-7.9% 8-8.9% >=9% 
Overall 2.72 (1.96, 3.78) 1.46 (1.12, 1.90) Ref 1.09 (0.76, 1.54) 1.66 (1.21, 2.27)  
Gender       0.02 
    Male 2.55 (1.62, 4.00) 1.90 (1.35, 2.68) Ref 1.00 (0.61, 1.65) 1.78 (1.16, 2.73)  
    Female 2.92 (1.79, 4.77) 0.94 (0.62, 1.44) Ref 1.20 (0.73, 1.98) 1.46 (0.91, 2.33)  
Current insulin use      0.01 
    Yes 3.05 (1.41, 6.55) 2.88 (1.69, 4.93) Ref 1.30 (0.74, 2.29) 2.74 (1.66, 4.52)  
    No 2.46 (1.70, 3.55) 1.17 (0.87, 1.59) Ref 1.14 (0.72, 1.82) 1.11 (0.70, 1.75)  
Current Sulfonylureas use       <0.0001 
    Yes 2.80 (1.68, 4.67) 1.87 (1.28, 2.72) Ref 0.76 (0.44, 1.34) 0.79 (0.46, 1.34)  
    No 2.50 (1.62, 3.87) 1.13 (0.78, 1.64) Ref 1.44 (0.91, 2.29) 2.58 (1.71, 3.90)  
All models adjusted for age in years, gender, BMI, Charlson score, duration of diabetes, current insulin user (y/n), current   sulfonylureas user 
(y/n), years of registration, smoking status (non-smoker, current smoker, ex-smoker and unknown), current use of  
antihypertensive drugs (y/n), specific diseases (y/n), current metformin user (y/n), and current other anti-diabetic drug user (y/n). 
* P value was from the interaction term between HbA1c categorical variable and each of the stratification variables in the fully adjusted model. 
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gender, race, duration of diabetes, parental education, BMI, percent on insulin pump, insulin 
dose per kilogram, physical activity and HbA1c. Another aspect of selection is related to the 
inclusion criteria for the FL3X trial participants. Eligible participants were aged 13-16 years at 
study entry who had HbA1c 8-13% and duration of diabetes >1 year. Thus, our study sample is 
not representative of all adolescents with type 1 diabetes.   
 
Methodological limitations  
 Nested-case control design studies relative risk ratio directly, not absolute risk difference. 
Translating or interpreting results from Aim 2 analyses should consider both the magnitude of 
the association and the background incidence of hypoglycemia hospitalization. For example, in 
adults with type 2 diabetes, compared to HbA1c 7-7.9%, HbA1c <6.0% was associated with 
218% and 165% higher risk of hypoglycemia hospitalization in current sulfonylureas users and 
insulin users, respectively. However, the incidence of hypoglycemia hospitalization in current 
insulin users was 2.7 times that in sulfonylureas users (Table 6.2). Therefore, although the  
association was slightly stronger in current sulfonylureas users, insulin users contributed more 
episodes of hypoglycemia hospitalization to associated healthcare systems. Similarly, among 
type 2 adults who were not currently on insulin and sulfonylureas, HbA1c ≥9.0% was associated 
with 248% higher risk of hypoglycemia hospitalization compared to HbA1c 7-7.9%. However, 
the incidence of hypoglycemia hospitalization was about 10% of the incidence in current 
sulfonylureas users; thus increased risk of severe hypoglycemia in adults who were currently not 
on insulin and sulfonylureas generated substantially less burden to the healthcare system. 
Nonetheless, due to the life-threatening but preventable nature of severe hypoglycemia, reducing  
 
 103 
 
Table 6.2. Estimated incidence rate of hypoglycemia hospitalization in adults with type 1 and 
type 2 diabetes, overall and by subgroups (in type 2 only) 
 Number of 
Cases  
Person years Incidence rate per 
1000 
Type 1 diabetes, total 311 35,127.75 8.85 
Type 2 diabetes, total 1,738 1,002,685.12 1.73 
Subgroups    
Status of current insulin 
and sulfonylureas use* 
   
    Neither  114 553,182.75 0.21 
    Sulfonylureas use only 825 334,216.33 2.47 
    Insulin use only  550 82,620.98 6.67 
    Both 249 32,665.06 7.62 
 
any risk of severe hypoglycemia is important to everyone with diabetes, regardless of 
population-level impact. 
 Two days of 24-hour dietary recall may not capture usual dietary intake. In fact, 
capturing the true usual dietary intake is difficult and a critical challenge to all relevant nutrition 
studies. Currently available dietary assessment tools all have limitations.151 Two days of 24-hour 
dietary recall in two unannounced days may be a best dietary assessment method to capture usual 
dietary intake in one study week, balancing the accuracy and participant burden. Ideally, dietary 
intake from one weekday and one weekend day are collected, but this did not happen all the time 
in our study. Further, with using dietary recalls, reporting bias may be possible. Our study 
participants were interviewed using multiple pass approach to reduce under-reporting.125, 126 
 
Confounding bias 
 Missing data is a common problem in electronic medical record data. For example, BMI 
and smoking status had missing data in our study. We categorized these two variables and 
grouped missing data into a separate category. Therefore, residual confounding is likely. Further, 
the CPRD lacks information on race, diet, physical activity, and individual-level variable of 
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social economic status, but they are not considered as the strongest confounders for severe 
hypoglycemia.  
 
Limitations associated with insufficient sample size 
 We are unable to study both first episode and all episodes of hypoglycemia. 
Hypoglycemia is a recurrent event. Previous history of hypoglycemia is a strong independent 
risk factor for future episodes of hypoglycemia.115, 117 Further, first episode of severe 
hypoglycemia and recurrent episodes may represent different etiology and lead to different 
consequences.115 For Aim 1, our main focus was to quantify the hypoglycemia burden to the 
healthcare system in England; thus all episodes of hypoglycemia were considered. However, we 
also analyzed trends of first hypoglycemia hospitalization in patients with incident diabetes. We 
found that in adults with incident type 1 diabetes, the risk of hypoglycemia hospitalization did 
not increase in the previous two decades. The trends in adults with incident type 2 diabetes were 
consistent with our main analyses; the decline since 2009 was also observed. However, due to 
the limited cases with hypoglycemia hospitalization, stratified analyses were not possible to 
assess whether trends of first hypoglycemia hospitalization were similar by important patient 
characteristics. For Aim 2, although our databases are large, studying first hypoglycemia 
hospitalization in type 1 diabetes is still not possible. In type 2 diabetes, the U-shaped association 
including the magnitude of the association remained when only first episode ever of 
hypoglycemia hospitalization was studied (Table 6.1).  For Aim 3, it is unlikely to identify first 
episode of non-severe hypoglycemia after diabetes diagnosis because it may be asymptomatic. 
 In the original proposal, we planned to study how hypoglycemia is treated by dietary 
intake in adolescents with type 1 diabetes. Current recommendations suggest using glucose, 
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sucrose or any form of carbohydrate to treat hypoglycemia.30, 77 However, we have very limited 
information related to how various forms of carbohydrate and other macronutrients either alone 
or in combination influence recovery of hypoglycemia. We proposed time to event analysis. 
Time in minutes from food intake to blood glucose rising back to 70 mg/dL or higher was the 
outcome and nutrients consumed within a meal were exposure. Preliminary analyses found that 
<60 episodes of hypoglycemia could be used for this purpose. Thus, we focused on how usual 
dietary intake predicts occurrence of hypoglycemia, not recovery.  
 Although our study is the largest dietary study in the CGM setting, the sample size is still 
not large, which precludes assessment of interaction among major macronutrients. Evidence has 
shown that interactions between protein, fat, and carbohydrate exist.90 Protein and fat have an 
additive impact on the delayed postprandial glycemic rise.82 In spite of the small sample size, we 
explored the interactions between protein, fat, and carbohydrate, but no interaction was found. 
Further, the small sample size also precludes evaluation of effect modification for the association 
of dietary intake with hypoglycemia by baseline glycemic status, diabetes duration, and pubertal 
status. Previous studies have shown that puberty and duration of diabetes are associated with 
glycemic control and insulin requirements in children with diabetes, and thus influence 
hypoglycemia risk.152 The data collection of the FL3X trial is ongoing. We will have follow-up 
data at 6 months and 18 months. Assessing of interactions and effect modifications may be 
possible when full data collection is complete.  
 
Limitations associated with longitudinal electronic health record data 
 Misclassification of diabetes and diabetes type may be possible by using electronic health 
record data, although the differentiation between type 1 and type 2 diabetes is also a major 
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strength of our study. A systematic review highlights a few issues relevant to diabetes 
classification using medical record data:153 distinction between diabetes and not diabetes, 
classification between type 1 and type 2 diabetes, and diagnostic errors/difficulties regarding to 
differentiate diabetes types other than type 1 and type 2. Our definition was adopted from 
published CPRD studies but modifications were made to reflect specific differentiation between 
type 1 and type 2 diabetes.102-104 For example, we did not use age <35 or 25 years as a criterion 
to differentiate diabetes type, because the prevalence of type 2 diabetes has been increasing in 
adolescents and young adults.154 Also, two, not only one, type 2 diabetes codes were required for 
diagnosing type 2 diabetes if anti-diabetic medication prescriptions were not available. Further, 
we excluded patients with any record of secondary diabetes, maturity onset diabetes of young, 
latent autoimmune diabetes in adults, and malnutrition related diabetes. Accordingly, it is highly 
unlikely that our findings would be biased by the misclassification of diabetes type. 
 With the introduction of the QOF since 2004 which is a voluntary incentive scheme for 
general practitioners,155 there has been more complete coding and documentation within the 
CPRD.99, 156 Further, in April 2006, diabetes type specific Read code for type 1 diabetes (the 
C10E hierarchy: C10E0 to C10EP) and type 2 diabetes (the C10F hierarchy: C10F0 to C10FQ) 
were introduced for use, in addition to the higher level general Read code for diabetes (C10 and 
any codes below it in the hierarchy). The introduction of C10E and C10F facilitates the 
differentiation of diabetes type, but only using them underestimates prevalence of diabetes.156 
Our case definitions for diabetes utilize both general diabetes codes and type 1 and type 2 codes 
together with prescriptions of anti-diabetic medication. Therefore, under-ascertainment is less 
likely. Adjusting for these two changes involves complex modeling and is out of the scope of 
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this work. Notably, we did not observe any significant change in hypoglycemia trends around 
2004-2006. 
 HbA1c data are not completely recorded in the CPRD although they appear to be widely 
available for patients with diabetes. From 2003 onward, practices within the CPRD began to use 
automated approaches to request tests and receive results from laboratories. Test data from this 
time are likely to be more complete than earlier years when paper-based systems were widely 
used.  We evaluated the effect modification by calendar year for the association between recent 
HbA1c level and risk of hypoglycemia hospitalization. However, the association did not vary by 
time.  
 
Other limitations 
 The form of severe hypoglycemia studied in this research is hypoglycemia requiring 
hospitalization which only accounts for a small proportion of all severe hypoglycemic events. A 
study from the DPV Prospective Diabetes Registry reported that hypoglycemia requiring 
hospitalization accounts for <10% of total severe hypoglycemia defined as low blood glucose 
event requiring external assistance.71 By analyzing data from the 1993-2005 National Hospital 
Ambulatory Medical Care Survey in the US,  Ginde et al. found that about 25% of severe 
hypoglycemia from emergency department visits resulted in hospital admission.52 Therefore, the 
results from Aim 1 and 2 analyses may not be generalized to all forms of severe hypoglycemia. 
 There are multiple dimensions to evaluate hypoglycemia, including occurrence, duration, 
lowest blood glucose, and timing of occurrence. In Aim 3, we focused on occurrence and timing 
of occurrence only. We did not consider the severity of hypoglycemia which is related to 
duration of low blood glucose <70 mg/dL and the lowest glucose concentration within a 
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hypoglycemic episode. Further, our definition of nocturnal hypoglycemia is arbitrary, although 
literature commonly defines nocturnal hypoglycemia using 11PM-7AM cutoff.130, 144  
 
Strengths 
 The major strengths of our investigation include distinguishing between type 1 and type 2 
diabetes, assessing long-term hypoglycemia trends covering almost two decades, studying 
HbA1c-hypoglycemia relationship using recently measured HbA1c rather than earlier HbA1c 
measurements, and assessing usual dietary intake and hypoglycemia risk in an outpatient 
environment instead of controlled settings.  
 The primary strength is that we investigated hypoglycemia in type 1 and type 2 diabetes 
separately in Aim 1 and 2. As explained in Chapter 2, type 1 and type 2 diabetes have very 
different etiology and require different treatment strategies, resulting in different risk of 
hypoglycemia. This distinction is critical to obtain results with clear, accurate, and targeted 
implications. A study led by Zaccardi et al.55 published in the Lancet Diabetes & Endocrinology 
in June 2016 reported that the hospital admission rate for hypoglycemia increased between 2005 
and 2014 in England, using the HES data. After adjusting for diabetes prevalence, the hospital 
admission rate showed a reduction since 2010. Zaccardi et al. did not distinguish type 1 and type 
2 diabetes. Our analyses found that the trends of hypoglycemia hospitalization differed by 
diabetes type and the decline was seen only in elderly adults with type 2 diabetes since 2009. 
Undoubtedly, our results presented a clearer picture of longitudinal trends of hypoglycemia 
hospitalization in England and had clearer implications. Further, our analyses also suggest 
differential associations of HbA1c with risk of hypoglycemia hospitalization between type 1 and 
type 2 diabetes.  
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 To our knowledge, our study is the longest study of trends in severe hypoglycemia in 
diabetes (1998-2013), which covers most of the time after the publication of major findings from 
the DCCT study in 1993.32 The longitudinal hypoglycemia trends we found may be used to 
evaluate and inform how the major changes in diabetes management and technologies in the 
previous two decades influenced risk of severe hypoglycemia over time, at least in England.  
 We used HbA1c measured within 3 months of hypoglycemic events to study the 
association between HbA1c level and risk of hypoglycemia hospitalization. All published studies 
used “baseline” HbA1c value measured more than three months or even years before,  38, 72-75 
which may be less relevant to the acute event of severe hypoglycemia. This may be the reason 
that stronger association between HbA1c and risk of severe hypoglycemia in type 2 diabetes was 
found in our study, although the U-shaped HbA1c-hypoglycemia relationship is consistent with 
the literature.72, 73 
 The majority of existing data related to dietary intake, postprandial blood glucose, and 
hypoglycemia are from clinical trials. However, as with any experimental study, the translation 
of clinical trial findings to an outpatient environment is uncertain. Also, previous literature has 
primarily focused on postprandial glycemic excursions following one or more pre-designed 
meals. Data on how nutrients from usual dietary intake impact hypoglycemia risk in an 
outpatient setting are lacking. Our study filled these gaps and is also the first study to identify 
soluble fiber and fat quality as two new dietary risk factors of non-severe hypoglycemia in 
adolescents with type 1 diabetes. 
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Significance and implication 
 Reducing the rapidly growing burden of hospital admissions for hypoglycemia in 
England is urgent. The risk of hypoglycemia hospitalization is high in type 1 diabetes and has 
steadily increased in the previous two decades. In type 2 diabetes, subgroups (e.g., current 
insulin or sulfonylureas users) with markedly high incidence of hypoglycemia hospitalizations 
also have large annual increase in trends. Therefore, the increased hypoglycemia burden is 
mainly attributed to type 1 diabetes and insulin or sulfonylureas treated type 2 diabetes in adults. 
Practical approaches for reducing hypoglycemia burden of the healthcare system in England 
need to primarily target at these patients.  
 Although all forms of severe hypoglycemia are important, hypoglycemia requiring 
hospitalization deserves particular attention.157 Hypoglycemia hospitalization creates 
considerable burden to related healthcare system and is associated with significant use of 
healthcare resources. A CPRD study reported a mean direct cost of £1034 and a mean hospital 
stay of over 5 days per admission for hypoglycemia; no difference was found between type 1 and 
type 2 diabetes.98 However, this study is likely to underestimate the cost. A review reported that 
the mean direct cost was €2807 (total cost €3917) per episode of severe hypoglycemia that 
requires inpatient care.157 Accordingly, even small increase in the incidence of hypoglycemia 
hospitalization would generate substantially more cost. Reducing the burden of hypoglycemia 
hospitalizations in England is medically and economically urgent. 
 There may still be an inappropriate impression that the lower frequency of hypoglycemia 
in patients with type 2 diabetes means that it is of less clinical importance.158 Although 
hypoglycemia occurs about 2 to 4 times more often in type 1 diabetes, type 2 diabetes accounts 
for over 90% of total diabetes cases.12  In insulin-treated patients with type 2 diabetes, 
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hypoglycemia is common, too.51, 159 In fact, it can be potentially more dangerous in patients with 
advanced type 2 diabetes because they are often older and may have multiple comorbidities. 
Based on our data, 1,591 hospitalizations for hypoglycemia occurred in adults with type 1 
diabetes while 3,738 occurred in adults with type 2 diabetes during the entire study period. Both 
diabetes types contribute significant hypoglycemia burden.  
 Although current clinical practice guidelines recommend personalized glycemic targets to 
maximize benefits and minimize harms (particularly hypoglycemia) of glycemic control 
therapies,14, 15 the association of HbA1c level with severe hypoglycemia is controversial. Our 
study confirmed the U-shaped HbA1c-hypoglycemia relationship in type 2 diabetes. In type 1 
diabetes, we found that higher HbA1c is related to lower risk of hypoglycemia, but this does not 
mean that we should apply less aggressive therapy to patients with type 1 diabetes, because 
poorly controlled HbA1c is associated with increased microvascular and macrovascular events 
that are the major cause of mortality and morbidity in diabetes.32, 160 Deciding an individual’s 
HbA1c target has to appropriately balance long-term glycemic benefits and short-term 
hypoglycemia risk. Guidelines recommend physicians to consider each patient’s hypoglycemia 
risk factors before prescribing treatment,14, 15, 62, 63 which is in line with our findings. In addition 
to diabetes type, obesity status in type 1 diabetes and current anti-diabetic medication in type 2 
diabetes are two other factors for consideration. 
 Our findings suggest that reducing hypoglycemia risk is not possible if correct insulin 
dose is not correctly injected at correct time to match dietary intake in youth with type 1 
diabetes. Current insulin dose calculation primarily based on carbohydrate counting may not 
sufficiently optimize postprandial glucose and reduce glycemic fluctuations which ultimately 
lead to hyper- and hypoglycemia.82, 90, 134 For the first time, we found that soluble fiber is 
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positively associated while monounsaturated and polyunsaturated fat are negatively associated 
with risk of hypoglycemia in adolescents with type 1 diabetes. These findings imply that refining 
future insulin dosing algorithms may also need to consider quality of carbohydrate and fat, but 
these results need to be confirmed in other studies first. Further, the current recommendation of 
injecting insulin about 15 minutes before a meal may also need to adjust, because it may not 
suffice the complexity of insulin dosing. The timing of insulin delivery is influenced by meal 
composition, blood glucose concentration at insulin injection, previous exercise, and 
pharmacokinetics of the injected insulin.142, 143 However, this is a hypothesis based on our 
findings, since we do not have relevant data on timing of insulin injection. 
 Hypoglycemia is a major barrier of optimal glycemic control both in type 1 and type 2 
diabetes, and in children and adults. However, a large European survey found that during routine 
appointment, 17% of those with type 1 diabetes and 21–28% with type 2 diabetes reported not 
being asked about hypoglycemia by their physicians;25 65% of people with type 1 diabetes and 
50–59% of people with type 2 diabetes who experienced a non-severe hypoglycemic event rarely 
or never informed their physicians. Physicians and patients should pay more attention and work 
together to overcome high hypoglycemia risk in diabetes. Although hypoglycemia is a 
multifactorial problem and is complex, but it is preventable,12 without the need of sacrificing 
optimal glycemic control.111 Approaches known to effectively reduce the risk of hypoglycemia 
include patient education, dietary and exercise modifications, medication adjustment, careful 
glucose monitoring by the patient, and conscientious surveillance by the clinician.12 Our study at 
least proposed two ideas to reduce hypoglycemia: 1) HbA1c targets need to be individualized; 2) 
different insulin dosing strategies may need for different nutrients/diet. The amount and quality 
of major macronutrients are both important. Timing of insulin injection may also be crucial.  
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Future directions 
 We are involved in a long battle to overcome hypoglycemia in diabetes. This research 
provides informative clinical and nutrition data to address three literature gaps and advances 
current understanding of hypoglycemia from population, individual, and behavioral perspectives. 
However, future work is critically and urgently needed to carry on, supplement or expand our 
current investigation.  
 Continuously monitoring trends of hypoglycemia hospitalization in adults with type 1 
and type 2 diabetes in England is needed. This is important, because we will know over time: i) 
if the increasing trends are reversed in type 1 adults and in young and middle aged adults with 
type 2 diabetes; ii) if trends of hypoglycemia hospitalization in elderly adults with type 2 
diabetes continue to decline. If any clinical practice level or policy level efforts are made to 
reduce hypoglycemia risk after our findings are published in a peer-reviewed journal, continuous 
monitoring allows to assess the effectiveness of actions. 
 Trends of a most severe form of hypoglycemia, hypoglycemia leading to hospitalization, 
are studied in this research. However, diabetes type-specific trends of severe hypoglycemia 
resulting in emergency room visits but not being hospitalized have not been studied in a time 
frame that is sufficiently long enough to cover most of time post the DCCT study. Quantifying 
incidence and trends of severe hypoglycemia not leading to emergency room visits or 
hospitalization is difficult using currently available longitudinal electronic health record data. 
Patients may not tell their physicians all severe hypoglycemic events they experienced and 
physicians may not record reported events into medical records. Relatively complete recording 
of severe hypoglycemic events into medical records in the future requires efforts from patients, 
health professionals, and policy makers. 
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 Our current analyses do not account for daily dose of anti-diabetic medication over time. 
As explained, the majority of hypoglycemic events are iatrogenic and different medications at 
different dose are associated with very different risk of hypoglycemia. Current analyses only 
consider generic types of anti-diabetic medication. We do not know if accounting for daily drug 
dose modifies hypoglycemia trends and HbA1c-hypogycemia relationship identified from the 
present study. Future work is encouraged to confirm this. 
 Current diabetes treatment guidelines broadly recommend less stringent glycemic control 
to patients who are vulnerable to hypoglycemia. A number of risk factors for hypoglycemia are 
listed to help define high risk patients for hypoglycemia. Just knowing these factors probably 
raises physician attention when prescribing intensive treatment, but it is difficult for physicians 
to decide the optimal glycemic target for each patient. An algorithm that predicts an individual’s 
hypoglycemia risk at different glycemic targets may be useful as a tool for physicians to decide a 
most appropriate glucose control therapy and for patients as a self-management tool to reduce 
risk of severe hypoglycemia. Ideally, such a risk prediction algorithm may need to consider 
patient behavior (e.g., diet, physical activity) as a parameter in addition to demographic, clinical, 
and therapeutic information.  
 Convincing evidence has revealed that calculating prandial insulin dose should be based 
on the complete meal composition. However, we currently do not have simple and easy-to-use 
insulin algorithms for fat and protein. A number of studies have assessed insulin dosing 
strategies for different meals including various bolus types, timing of the meal bolus, and 
methods to calculate the bolus dose.90 In the short term, to reduce currently high hypoglycemia 
risk in children with type 1 diabetes, a few insulin dosing algorithms incorporating dietary fat 
and protein can be designed based on available data and tested for efficacy. Guidelines can be 
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modified accordingly to improve current recommendations for calculating insulin dose. In the 
long run, the following questions need to be answered in order to design better insulin dosing 
algorithm to optimize postprandial glucose concentration:90 i) Are effects of all types of fat and 
protein on postprandial blood glucose similar? Our study suggests unsaturated fat, not saturated 
fat, is negatively associated with hypoglycemia, but more evidence is needed. ii) The inter-
person differences of glycemic excursions in response to the same nutrients or diet further 
complicate designing insulin dosing algorithms. Future studies need to explore if certain 
phenotypic characteristics can be used as markers to identify individuals who are more nutrient 
sensitive and require to adjust insulin dose and delivery patterns. iii) Is there a threshold and/or 
dose response for insulin dose and fat/protein relationship? iv) how carbohydrate, fat, and protein 
interact with each other to influence postprandial glucose excursions and hypoglycemia risk is 
not yet fully understood. v) Is injecting insulin about 15 minutes before mealtime a good 
criterion for all circumstances including different meals and different insulin? 
 
Conclusion 
 The advance in diabetes management in the past few decades —including the better 
understanding of the relationship between hypoglycemia and hyperglycemia, availability of new 
anti-diabetic drugs, and new technologies— has not necessarily contributed to improved control 
of hypoglycemia. Surprisingly, in Aim 1 at population level, we found that hypoglycemia 
requiring hospitalization has been an increasing burden in adults with type 1 and type 2 diabetes 
in England in the previous two decades, with the exception of the decline in elderly adults with 
type 2 diabetes starting in 2009. We then explored two hypoglycemia prevention strategies. In 
Aim 2 from individual perspective, our findings suggest that glycemic targets (long-term 
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glycemic control) need to be individualized to reduce hypoglycemia risk. In Aim 3 from 
behavioral perspective, optimizing day-to-day blood glucose level (short-term glycemic control) 
via optimal insulin dosing matching to dietary intake may be critical for preventing 
hypoglycemia. However, to overcome hypoglycemia as a multifactorial problem, multi-
dimensional approaches are needed in addition to the two studied in our project, including 
patient education, family/social support, and careful self-monitoring of blood glucose. Future 
hypoglycemia prevention therapies need to consider all these aspects.  
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